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Abstract 
The causative agent of tuberculosis (TB), Mycobacterium tuberculosis (Mtb), still remains one of 
the most serious infectious diseases with 10 million new reported cases in 2015. Although TB is 
curable, the ability to acquire resistance to various antibiotics by the Mtb organism is well 
known. The emergence and spread of multidrug resistance (MDR) and extremely drug resistance 
(XDR) Mtb strains, along with HIV/TB co-infections, has put TB control programmes in 
jeopardy, particularly in developing countries. Therefore, there is a continuous need to search for 
new structural classes of anti-TB drugs with novel modes of action and ideally no cross 
resistance to current drugs to treat both sensitive and resistant forms of TB. 
Fusidic acid is a naturally occurring antibiotic used to treat Gram-positive bacterial infections. It 
has potent activity against S. aureus and is clinically used to treat mild to moderately severe skin 
and soft-tissue infections. The mode of action of fusidic acid involves the inhibition of protein 
synthesis via binding to bacterial elongation factor G (EF-G). Fusidic acid has also been reported 
to possess in vitro antimycobacterial activity but was subsequently found to lack in vivo efficacy 
in a mouse model.  
Towards contributing to new antimycobacterial agents, this study focusses on repositioning 
fusidic acid for tuberculosis by employing prodrug and bioisosterism approaches through 
structural modifications at the C-3, C-11 and C-21 positions of the drug (Figure 1). Accordingly, 
C-21 derivatives 3.2 and 3.3 were synthesized by a one-step coupling reaction, while C-3 
analogues 3.8 and 3.9 were synthesized by a three step synthetic protocol involving esterification 
followed by coupling with hydrazine monohydrate and mesylation. The other C-3 esters 3.10-
3.22 were synthesized via Steglich esterification. The C-3 target compound 3.26 was synthesized 
vi 
 
using a 4-step synthetic route. The first step involved an acid-amine coupling reaction, which 
was followed by mesylation, Jones oxidation and then reductive amination of the resulting 
ketone.  
 
Figure 1: Graphic abstract of synthesized compounds 
The synthesized compounds were characterized on the basis of nuclear magnetic resonance 
(NMR) spectroscopy, mass spectrometry (MS), high performance liquid chromatography 
(HPLC), thin layer chromatography (TLC) and melting point (m.p.).  
Relative to fusidic acid (MIC99 of 0.49 µM), this set of analogues exhibited good to poor in vitro 
activity against the H37Rv strain of Mtb in glycerol-containing media glycerol-alanine-salt with 
Tween-80 and iron (GAST/Fe), with compounds 3.4, 3.5, 3.8 and 3.21 showing promising MIC99 
values in the range of 0.49–7.81 µM. However, compounds 3.8 and 3.21 were inactive in the 
7H9 GLU/ADC media containing glucose as a carbon source. 
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Structure-activity relationship (SAR) studies suggested that the C-3 and C-11 hydroxyl, as well 
as the C-21 carboxylic acid functional groups are necessary for antimycobacterial activity. 
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CHAPTER 1 
1. Tuberculosis 
1.1 Disease and epidemiology  
Tuberculosis (TB) is a prevalent and often fatal infectious disease that has existed for millennia.
1
 
The causative agent of TB in humans is the pathogenic bacteria Mycobacterium tuberculosis 
(Mtb), which was originally identified by Robert Koch in 1882 as a slow growing, nonmotile, 
aerobic and rod-shaped bacterium.
2–4
 The history of mycobacteria is believed to have come from 
soil-dwelling ancestors, which subsequently became pathogenic to humans after animal 
domestication about 70 000 years ago.
5
 Other TB causing agents, which are closely related to 
Mtb includes M. bovis, M. africanum, M. microti and M. canetti, which are referred to as the 
mycobacterial complex.
6
  
Tuberculosis was declared a public health emergency in 1993 by the World Health Organization 
(WHO) as it was reaching pandemic levels. According to the WHO, in 2015 it was reported that 
10.4 million new cases of TB were recorded with 1.8 million TB-related deaths. In the same 
period, TB was the number one cause of death globally after the human immunodeficiency virus 
(HIV), with HIV/TB co-infections accounting for more than 0.4 million deaths worldwide.
1,7,8
 
Overall, 95% of TB related deaths occurred in developing countries, with countries in Asia 
(India, Indonesia, China and Pakistan) and Africa (Nigeria and South Africa) accounting for 60% 
of all TB cases. Although, there has been a decline in TB incidences since 2000, complete TB 
eradication by 2030 is the target for the WHO.
1
 Figure 2 shows the global TB incidence for 
2014.  
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Figure 2: Global TB incidence for 2014.
1
 
1.2 Transmission and pathogenesis 
Mtb is an airborne pathogen transmitted through coughing and sneezing. The primary site of 
infection is the lungs (pulmonary TB), from which the bacterium can enter the blood stream and 
infect other sites such as the lymphatic and genitourinary systems as well as bones and joints as 
extrapulmonary TB.
2,7 
Once in the lung, the Mtb bacilli are phagocytosed by alveolar 
macrophages, the first line of defense against infections (Figure 3).
5
 
In the macrophages, phagosome maturation takes place to eradicate the bacterial infection, but 
Mtb has developed mechanisms to escape and survive within these macrophages as compared to 
other mycobacterial infections. For example, due to the low oxygen tension and limited nutrients 
in the macrophages, Mtb can shut down its own metabolism thus terminating replication and 
transiting into dormancy, a state known as latent TB.
5,9
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As the macrophages migrate, Mtb is transported from the alveolus to pulmonary tissue sites. To 
prevent further infection and spread of Mtb, the infected macrophages forms a granuloma. The 
cellular composition of granuloma lesions include infected or uninfected macrophages, B and T 
lymphocytes and fibroblasts (Figure 3).
9,10
 The survival of Mtb within the granuloma can be 
attributed to its impermeable thick cell wall that is made up of peptidoglycans, polysaccharides, 
glycolipids and lipids such as mycolic acid.
5
  
 
Figure 3: Transmission and pathology of tuberculosis. Transmission of TB between 
individuals occurs via aerosols of infected bacilli. Upon inhalation of infected bacilli, the 
pathogen reached the lungs where it is phagocytosed by alveolar macrophages. Healthy 
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individuals can control the pathogen, but the Mtb can grow to a high numbers, realizing the 
infected bacilli in the airways and coughing them out as aerosol.
5
 
In an immunocompetent individual, Mtb can persist within the granuloma for decades without 
symptoms of infection.
5
 Once the immune system is compromised, Mtb becomes metabolically 
active and starts to replicate, resulting in the collapse of the granuloma and release of the virulent 
bacilli to other tissues or transmission to other individuals (Figure 3).
5,6,9–11
 Immune 
compromisation can occur in children or old age populations, individuals on 
immunosuppressants and people who are HIV positive or malnourished.
12
 The symptoms of 
active TB include weight loss, poor appetite, night sweats, fever, productive or dry cough and 
chest pains.
12,13 
1.3 Anti-TB drugs 
Tuberculosis chemotherapy is based on antibiotic drugs, which were discovered in the 20
th
 
century and, since the 1960’s, the rate of antibiotic drug discovery has been on the decline.
14
 
Shortly after the introduction of streptomycin in 1946 as an effective monotherapy treatment for 
Mtb, streptomycin-drug resistance was observed, which led to the adoption of combination 
therapy.
15
 Currently, TB therapy consists of drugs that can be classified based on their efficacy, 
potency, drug class and experience of use (Table 1). The first-line drugs (Group 1) are used to 
treat drug-susceptible TB (DS-TB), except streptomycin (SM), which is classified as an 
injectable drug (Group 2). Drugs in Groups 2-5 (except streptomycin) are all second-line drugs 
used for resistant TB treatment. These second line drugs are further divided into their respective 
groups based on features such as cross-resistance.
16
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Table 1: Drugs for TB treatment.
16–20
 
Groups Drugs 
Group 1: 
First-line oral agents 
Isoniazid (INH), Rifampicin (RIF), Rifapentine, Pyrazinamide (PZA), 
Ethambutol (EMB), Rifabutin 
Group 2: 
Injectable agents 
Aminoglycosides: Kanamycin, Amikacin, Streptomycin (SM),  
Polypetide: Capreomycin  
Group 3: 
Fluoroquinolones 
Levofloxacin, Moxifloxacin, Ofloxacin, Gatifloxacin 
Group 4: 
Oral bacteriostatic 
second-line agents 
p-Aminosalicylic acid, Cycloserine, Terizidone, Ethionamide, 
Protionamide  
Group 5: 
Drugs with limited 
efficacy or safety data 
Bedaquiline, Delamaid, Clofazimine, Linezolid, Amoxicillin/Clavulanate, 
Thioacetazone, Meropenem, Imipenem/Cilastatin, Clarithromycin  
 
1.4 Treatment 
The primary object of TB therapy is to (i) cure the infection without subsequent relapse, (ii) 
improve efficacy, safety and duration of treatment, (iii) improve the safety of combination 
therapy for TB patients co-infected with other chronic diseases, and (iv) establish an effective 
therapy for latent TB.
2,17,21
 The WHO therefore recommends a standard chemotherapeutic 
treatment regime under the “directly observed treatment, short course” (DOTS) and DOTS-Plus 
strategies. The DOTS strategies are designed to ensure completion of treatment and cure, with 
the success of these strategies largely dependent on commitment by various government 
agencies implementing the guidelines.
22
  
The regime for new non-multidrug resistant TB cases under DOTS comprises of the intensive 
and continuation phases. The intensive phase involves the administration of isoniazid (INH), 
rifampicin (RIF), pyrazinamide (PZA) and ethambutol (ETB) or streptomycin (SM, Figure 4) 
daily for two months. The tubercle bacilli are killed rapidly during this phase but, to avoid 
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relapse, the continuation phase is initiated. The continuation phase consists of INH and RIF for 
an additional four months.
13,17,22
 
 
Figure 4: First-line anti-TB drugs. 
HIV/TB co-infected patients can be treated using one of the following three regimes; (i) daily 
INH for six to nine months, (ii) daily INH and RIF for 3 months or (iii) INH and RIF twice 
weekly for 3 months.
13
 
The DOTS-Plus recommends the use of five second-line drugs for multidrug resistant TB 
(MDR-TB). The choice of drugs is based on susceptibility testing of Mtb against available drugs. 
In the absence of susceptibility test results, the regime is based on factors such as drug resistance 
patterns in the geographic area, previous drug exposure, other underlying medical conditions or 
adverse effects of the drugs of choice.
16
 The commonly used regime consists of pyrazinamide 
(PZA), a fluoroquinolone, amikacin or kanamycin, ethionamide or prothionamide and 
cycloserine (recommended) or p-aminosalicylic acid (Figure 5). The regime for extremely drug 
resistant TB (XDR-TB) is non-existing, therefore, the same procedure as for MDR-TB is 
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recommended. Drug resistant TB (DR-TB) therapy is recommended for eighteen to twenty 
months.
13,16
 The current vaccine, M. bovis Bacillus Calmette-Guérin (BCG), is used as a 
protective measure for pediatric TB, but fails for pulmonary TB in adults.
5
 
 
Figure 5: Second-line anti-TB drugs. 
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1.5 Challenges  
Despite the valuable information amassed on the biology of mycobacteria, there are notable 
discrepancies and challenges that have prevented the complete eradication of TB worldwide. 
Such challenges include drug resistance, HIV/TB co-infections, drug-drug interactions, long 
treatment duration and a high pill burden.  
The long treatment period of six months to two years for DS-TB and DR-TB respectively, not 
only burdens the already compromised healthcare facilities found in most developing countries, 
but also contributes to the development of drug resistance.
1
 
Drug resistance in Mtb can be traced back to the late 1940s, after the introduction of the first 
antibiotics for tuberculosis treatment.
23
 There are two types of drug resistance; primary 
resistance, which occur in persons who have been infected with the resistant mycobacterium 
strain and secondary resistance, which develops during therapy, either by an inadequate regime 
or noncompliance of patients.
24
  
The two types of TB resistant strains that have been recognized by the WHO are MDR- and 
XDR-TB. MDR-TB is resistant to INH and RIF, the two most effective first-line anti-TB drugs. 
On the other hand, XRD-TB is characterized by resistance to INH, RIF, any fluoroquinolone and 
any second line injectable aminoglycoside.
25–27
 Some of the reasons for the development of drug 
resistance include:
28
 
 Deficient or deteriorating TB control programs  
 Improper prescription of regimens  
 Interruption of chemotherapy due to side effects  
 Non-adherence of patient to the prescribed drug therapy  
 The epidemic of HIV co-infection  
 Use of anti-TB drugs for indications other than tuberculosis.  
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A more concerning issue is the emergence of the more severe drug–resistant forms of TB, which 
is totally drug resistant (TDR-TB), and is defined as resistance to all first and second-line anti-
TB drugs.
3
 Although the diagnostic definition of TDR-TB is still pending, it is conceivable that 
treatment options for TDR-TB will be severely limited or non-existing.
29
 In addition, the drugs 
used for the treatment of drug resistant TB are associated with high toxicity and are expensive as 
compared to first-line drugs.
30,31
 
TB chemotherapy is further impeded by the existence of non-replicating forms of Mtb. These 
latent infections serve as a reservoir for future transmissions and contribute to the severity of the 
disease through the risk of reactivation as reported for immune-compromised individuals.
32
 
Some of the most crucial issues in the treatment of HIV-associated TB include unfavorable drug-
drug interactions and the additive toxicities associated with combined antiretroviral (ARV) drugs 
with TB drugs. For example, RIF cannot be co-administered with ARVs such as nevirapine 
(NVP), indinavir (IDV) and nelfinavir (NFV, Figure 6), since RIF is a powerful inducer of 
cytochrome P450 (CYP) enzymes. These enzymes are responsible for metabolizing ARVs to 
their inactive metabolites, thus reducing the effective serum concentration and exposure. Hence, 
patients are forced to complete TB treatment before beginning HIV treatment.
2,33
 The HIV/TB 
co-infection causes a faster progression of each other.
7
 
 
Figure 6: ARV drugs with drug-drug interactions with RIF. 
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Therefore, the next generation of anti-TB drugs should preferably be fast acting, potent with 
novel modes of action, be able to shorten the treatment duration, effective against all drug-
resistant strains of TB, less toxic and safe to be co-administered with other chronic 
medications.
34,35
  
1.6 Current anti-TB drugs in the drug development pipeline  
There are several compounds currently in preclinical and clinical development as potential anti-
TB agents. Figure 7 shows the current anti-TB agents at different stages in the drug discovery 
and development value chain. These compounds are either new chemical entities or known 
compounds that have been repurposed for TB. 
 
 
Figure 7: Global TB drug development pipeline.
20,36,37
 
One of the many products in clinical development is Bedaquiline, which is the first compound to 
be approved by the United States Food and Drug Administration (FDA) in over 40 years as an 
anti-TB drug. Bedaquiline (Figure 8) was approved to be used in combination with at least 3 or 4 
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(DS-TB) 
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other drugs based on a susceptible in vitro test for the treatment of extrapulmonary TB, pediatric 
TB, TB in pregnant women, HIV/TB patients and MDR-TB in adults. The mechanism of action 
(MoA) involves inhibition of mycobacterial ATP synthase, an enzyme essential for energy 
generation (Figure 8).
38
  
 
Figure 8: Structure of Bedaquiline, delamanid and pretomanid. 
Two of the combination partners of Bedaquiline are nitroimidazoles delamanid and pretomanid 
(Figure 8). These compounds have inhibitory activity against both replicating and non-
replicating Mtb. Both of these drugs are activated by the deazaflavin (cofactor F420)-dependent 
nitroreductase enzyme.
39
 Pretomanid inhibits the formation of ketomycolate, a constituent of 
mycobacterial cell wall and by poisoning the bacterium with nitric oxide, a byproduct of 
nitroimidazole metabolism. Delamanid inhibits mycolic acid biosynthesis, a mycobacterial cell 
wall component (Figure 9) and was approved in 2014 by the FDA to treat MDR-TB in people 
who lack effective and tolerable treatments.
39,40
 Figure 9 indicates the MoA of anti-TB drugs in 
use or in preclinical and clinical stages of drug development.
35
 
 Chapter 1: Tuberculosis 
12 
 
 
Figure 9: MoA of anti-TB drugs in use or in preclinical and clinical stages of drug 
development.
35
  
In summary, since the high-TB burdened countries are mainly those in developing countries, the 
availability of inexpensive and easily accessible drugs will always be in demand. In addition, the 
next generation of anti-TB drugs have to be safe, tolerable and have both bactericidal and 
sterilizing activity.
41
 Most importantly, they should be short acting, to improve patient 
compliance and active against Mtb throughout its different states.
7,42
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CHAPTER 2 
2. Natural products 
For centuries, mankind has relied on natural products and their Semi-Synthetic derivative for 
their use in various industries such as in dyes, polymers, fibers, glues, oils, waxes, flavoring 
agents, perfumes and drugs.
43
 Of interest to this study are the medicinal properties of bioactive 
ingredients in natural products. The term natural product in this context refers to secondary 
metabolites produced by terrestrial and marine organisms such as plants, bacteria, fungi and 
algae.
44,45
 They are produced as an adaptive strategy to the environment or as a defensive 
mechanism against herbivores, pathogens, insects or competing plants. On the other hand, 
primary metabolites are used for cellular functions such as growth, development and 
reproduction.
44,46
 
Secondary metabolites can be characterized based on their composition, synthetic pathway and 
chemical structures as either (i) phenolic compounds containing benzene, hydrogen and oxygen; 
(ii) terpenes, which are hydrocarbons, or (iii) alkaloids, which contain nitrogen atoms.
45,46
  
This study looks at the involvement of natural products and their synthetic derivatives in drug 
discovery, especially for Mtb. 
2.1 Natural products in drug discovery 
There are extensive reports on the contribution of natural products and their synthetic derivatives 
to the drug discovery process. Natural products and their synthetic derivatives have therapeutic 
uses as exemplified by antibacterial, anticancer, immunosuppressive, cholesterol lowering and 
antiparasitic agents.
47
  
The discovery of penicillin in 1929 by Alexander Fleming from Penicillium notatum, brought 
about the “Golden Age of Antibiotics”, the period when most commercially used antibiotics 
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where discovered.
46,48
 Since then, natural products have continued to inspire drug discovery for 
both infectious and non-infectious diseases. As of 2014, 50% of all new approved drugs between 
1981 and 2014 were either natural products, inspired by natural products or natural product 
derivatives.
46,48,49
 Examples of drugs from natural products include, morphine, cocaine, codeine 
and quinine (Figure 10).
43
  
 
Figure 10: Structures of ancient natural products for medicinal use. 
In recent times, synthetic small molecules have taken precedence in drug discovery over natural 
products, even though nature holds limitless unexplored potential. Some of the reasons that 
contributed to the decline in natural products-driven drug discovery include; (i) limited natural 
product material, leading to low isolation yields; (ii) time constraints associated with isolation 
and structural characterization; (iii) synthetic difficulties during lead optimization or total 
synthesis due to structural complexity; or (iv) metabolic bioactivation of natural products to their 
toxic metabolites.
48,50–53
 Moreover, the introduction of combinatory chemistry and high 
throughput screening (HTS) to generate chemical diversity became an inexpensive and favorable 
route.
50,53
  
Although natural products have their limitations, they are still favorable in complementing drug 
discovery efforts due to, in some cases, their desirable physico-chemical and pharmacokinetic 
profiles, such as high solubility, appropriate lipophilicity, good oral absorption and low toxicity 
profile.
25,51
 In addition, natural products occupy various chemical spaces with structural features 
which, for many, are unconceivable to humans and highly desirable in drug discovery as 
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compared to synthetic compounds. These structural features include chiral centers, aromatic 
rings, complex ring systems, degree of saturation and heteroatoms.
43,52,54
 
2.2 Antimycobacterial natural products 
Natural products and their synthetic derivatives have shown to be a reliable source of innovative 
and effective therapeutic agents, especially between 1940 and 1970 when most anti-TB drugs 
where discovered. The discovery of the first anti-TB drug, streptomycin (Figure 11), isolated 
from Streptomyces griseus by Selma Abraham and co-workers in 1943, began an era where 
several natural products were discovered for antitubercular use.
25,46
 Other natural product 
inspired anti-TB agents are shown in Figure 11, with the year they were introduced to the 
market.
2,31,32,42,48
 
 
Figure 11: Natural product-inspired TB drugs. 
There are various natural products and natural product derivatives that have displayed potent in 
vitro inhibitory activities against susceptible and drug resistant Mtb.
48
 Of interest to this study are 
reports on the promising antibacterial activity displayed by the natural product fusidic acid. 
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2.3 Fusidic acid  
2.3.1 Chemistry of Fusidic acid  
Fusidic acid (Figure 12) belongs to the fusidane family of compounds and was first isolated from 
Fusidium coccineum fungus in 1960. The structural features of fusidic acid are; a tetracyclic ring 
system with a chair-boat-chair (trans-syn-trans) conformation, a carboxylic acid bearing side 
chain linked to the ring system at C-17 and an acetate group at C-16 (Figure 12).
55
 
 
Figure 12: Structures of fusidic acid; (a) numerical numbering of fusidic acid, (b) chair-boat-
chair conformation. 
2.3.2 Biology of Fusidic acid 
Fusidic acid is a narrow-spectrum antibiotic. Since 1962 it has been used to treat infections 
caused by both Gram-positive and Gram–negative bacteria.
56,57
 The various infections that 
fusidic acid is used against a range from boils, anthrax or carbuncle, erythema, cellulitis, 
folliculitis, acne, paronychia, hidradenitis, bone and joint infections to soft-tissue infections.
57–59
  
Amongst the fusidane family, fusidic acid is the only clinically used antibiotic, as other fusidanes 
are less active. Other naturally occurring fusidanes with antibiotic activity are shown in Figure 
13.
60–64
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Figure 13: Natural occurring antibiotic fusidanes. 
The therapeutic usefulness of fusidic acid is based on its high tissue distribution, good 
penetration, low toxicity and bacterial resistance, low allergic reaction and no cross-resistance 
with other clinical antibiotics. The mode of administration of fusidic acid is either oral (tablet 
and suspension), intravenous or topical (cream and ointment).
57–59
 
Although fusidic acid has the above mentioned advantages, there have been some reports of 
concern. For example, a clinical study of fusidic acid in combination with rifampin (RIF) for 
prosthetic joint infections was terminated due to drug-drug interactions between these two 
drugs.
65
 This combination was used for the treatment of staphylococci resistant strains.
66
 In 
addition, fusidic acid has been shown to have various side effects, which include gastrointestinal 
tract discomfort, diarrhea and headaches. A rarely reported side effect of fusidic acid is skin 
reactions (itching, rashes and dryness), but these adverse effects do not warrant a discontinuation 
of fusidic acid use.
57,67
 
Chapter 2: Natural Product and Fusidic Acid 
18 
 
The activity of fusidic acid against various infectious is generally bacteriostatic but bactericidal 
at high dosage. A bacteriostatic drug effect is the ability of the drug to inhibit bacteria 
proliferation while a drug bactericidal effect is the ability of a drug to promote microorganism 
death.
57
 The mode of action of fusidic acid is through inhibition of protein synthesis in 
prokaryotes and eukaryotes at the translocation step during elongation of the polypeptide. 
Fusidic acid binds to the elongation factor G (EF-G) and stabilizes the ternary complex EF-G-
GDP-ribosome. EF-G is essential for bacterial protein elongation on the ribosome after peptide 
bond formation.
57,68
 
Due to its mechanism of action, fusidic acid has been shown to have in vitro activity against 
various pathogens, as shown in Table 2. These antibacterial activities of fusidic acid have 
stimulated interest in the structural modification of this drug. 
Table 2: In vitro activity of fusidic acid against various species.
69,70
   
Species MIC90 (µg/ml) 
Staphylococcus aureus 
(methicillin susceptible) 
0.03 – 0.3 
Streptococcus pyogenes 4 – 16 
Streptococcus pneumoniae 2 – 16 
Streptococcus faecalis 1 – 8 
Neisseria honorrhoeae 0.03 – 4 
Neisseria meningitides 0.015 – 0.5 
Clostridium spp 0.06 – 1.0 
Peptostrep. spp 0.06 – 2 
Bacteroides fragilis 0.25 – 16 
Bacteroides spp 0.06 – 6 
Corynebacterium spp 0.06 – 12.5 
 
2.3.2.1 Structural Activity Relationship studies of fusidic acid (Antibacterial Study) 
Intensive structural-activity relationship (SAR) studies of fusidic acid have revealed that the 
tetracyclic skeleton and the carboxylic acid functionalities are of importance in order to maintain 
activity, while the side chain, in addition to the sterol backbone, is responsible for lipophilicity. 
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The double bond between C-17 and C-20 plays no apparent role in activity compared to the 
orientation of the lipophilic side-chain and can therefore be reduced. However, only the 17S,20S 
isomer shows equipotent biological activity to fusidic acid.  The two hydroxyl groups can be 
substituted with other functional groups such as keto, halogens, sulfoxides and azides, while 
maintaining antibacterial activity. The acetate group can be substituted with functionalities, such 
as, O-acyl, S-acyl and ethers and still maintain antibacterial activity (Figure 14).
55,59,71
 
 
Figure 14: Antibacterial SAR of fusidic acid. 
Within the context of TB, fusidic acid was found to have in vitro MIC90 (minimum concentration 
that will inhibit 90% of the bacterial population) of 1.2 µM against the H37Rv strain of Mtb, 
with no cross-resistance against first line anti-TB drugs.
72,73
 Due to these properties of fusidic 
acid, this study focusses on utilization of the drug repositioning strategy based on fusidic acid as 
a template for the semi-synthesis of new derivatives as potential antimycobacterial agents .  
2.4 Drug repositioning for TB 
A literature review revealed various strategies that have been used in the design and synthesis of 
potential anti-TB agents. One of the rewarding strategies is drug repositioning, which refers to 
the use of an existing drug developed for a specific disease indication as a template for further 
synthetic derivatization to improve on its pharmacological profile in a different disease 
indication.
74,75
 Examples of drugs that have been repositioned for TB are shown in Figure 15.  
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Figure 15: Repositioned drugs for TB.
76–79
 
The drug repositioning approach is advantageous since it is less expensive, reduces risks 
associated with drug discovery and it provides a shorter time period for drug development.
74,80
 
On the other hand, drug repurposing, a closely related strategy, is the use of an existing drug in a 
different disease indication without any chemical modification.
74,75
 Examples of drugs that have 
been repurposed for TB are shown in Figure 16. 
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Figure 16: Repurposed drug for TB treatment.
81
  
In view of the above mentioned advantages associated with drug repositioning, this project aims 
to reposition the natural product fusidic acid through the design and synthesis of potential novel 
antimycobacterial agents. 
2.5 Aims and Objectives  
2.5.1 Objective  
The objective of this project is to investigate antimycobacterial SAR of the natural product 
fusidic acid through semi-synthesis. 
2.5.2 Research question  
Can fusidic acid be repositioned for TB through medicinal chemistry SAR exploration? 
2.5.3 Specific aims 
Synthesis, characterization, in vitro antimycobacterial evaluation and SAR studies of fusidic acid 
analogues. 
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CHAPTER 3 
Design, synthesis and biological evaluation of fusidic acid derivatives 
3.1 Introduction 
This chapter describes the design, synthesis and characterization of fusidic acid derivatives. 
All the synthesized analogues were evaluated for their in vitro antimycobacterial activity 
against the virulent H37Rv strain of Mtb. 
3.2 Rationale 
An initial study conducted by Cicek-Saydam and co-workers on the in vitro susceptibility of 
170 clinical isolates of Mtb to fusidic acid and other drugs revealed that 19 isolates were 
resistant to one or more first-line anti-TB drugs. Three of the isolates were resistant to fusidic 
acid and the remaining 151 isolates were susceptible to first-line anti-TB drugs. Fusidic acid 
was also found to have no cross-resistance with first line anti-TB drugs.
72
 Furthermore, a 
High-Throughput Screen (HTS) conducted by the Tuberculosis Antimicrobial Acquisition 
Coordinating Facility (TAACF) revealed that fusidic acid has an IC90 of 1.20 µM against the 
H37Rv strain of Mtb.
73
  
In another study that was conducted by the Global Alliance for TB Drug Development in 
collaboration with Prof. Anne Leanerts of Colorado State University, fusidic acid was found 
to lack in vivo efficacy in a tuberculosis mouse model up to a dosage of 200 mg/kg. This 
finding is in agreement with that of Payne et al.,
68
 who found fusidic acid to have in vitro 
inhibitory activity against Toxoplasma gondii and Listeria monocytogenes but no in vivo 
efficacy in the corresponding mouse model.
68
 This lack of in vivo efficacy has been attributed 
to fusidic acid’s poor absorption in rodents, leading to a low serum concentration.
82
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Within this context, our research group has embarked on a multi-disciplinary approach to 
reposition fusidic acid for tuberculosis. This has involved medicinal chemistry, biology as 
well as drug metabolism and pharmacokinetic (DMPK) studies as follows; 
An in vitro drug-drug interaction analysis of fusidic acid against various current anti-TB 
drugs exhibited synergistic interaction, resulting into a 4-16 fold reduction in MIC values 
against M. smegmatis as determined by the Fractional inhibitory concentration (FIC) index 
(FICI).
83
 
The drugs used in this study included; rifampicin, streptomycin, spectinomycin, linezolid, 
roxithromycin, erythromycin, clarithromycin and tetracycline.
84
 This synergistic interaction 
against various antibiotics makes fusidic acid a promising lead to be repositioned as a 
potential anti-TB drug. 
Alongside this study, various fusidic acid analogues with different substituents at the C-3, C-
16 and C-21 were designed and synthesized by Dr. Gurminder Kaur, Dr. Kawaljit Singh and 
Ms. Antonina Wasuna from the Department of Chemistry, University of Cape Town (South 
Africa, Figure 17). This set of compounds were then evaluated for their antimycobacterial 
activity against the H37Rv strain of Mtb. 
An example of some of these compounds with promising in vitro antimycobacterial activity 
(MIC99 values 1.25-20 µM) is shown in Figure 17. These compounds were further tested for 
their in vitro antiplasmodial activity against the chloroquine (CQ)-sensitive NF54 strain of P. 
falciparum with IC50 values of 1.2-48.1 µM.
85,86
  
The design of these various fusidic acid derivatives was based on the initial hypothesis that 
the lack of in vivo efficacy was a result of poor cell wall permeation due to the carboxylic 
acid moiety. To circumvent this problem and potentially increase penetration, various ester 
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and amide analogues were synthesized as hybrids and bioisosteres of the carboxylic acid 
group, and as prodrugs of the C-3 hydroxyl.
85,86
 
 
Figure 17: Examples of fusidic acid derivatives at the C-3 and C-21 position with their 
respective MIC99 values against H37Rv strain of Mtb.
85,86
 
The in vitro assay results revealed that the amides and esters were found to be less potent 
than fusidic acid with MIC99 values ranging from 2-8 folds lower than that of fusidic acid. 
These hybrid analogues were also found to be cytotoxic against two mammalian cell lines 
[Chinese Hamster ovarian (CHO) and THP-1 cell].
85,86
 
Compounds GKFA16, GKFA17 and GKFA37 (Figure 17), which displayed better 
extracellular antimycobacterial and toxicity profiles, were progressed to macrophage 
(intracellular) efficacy studies. These compounds were found to reduce the bacterial burden 
in infected human monocytic cells (THP-1) at concentrations two or five times higher than 
their inhibitory concentrations in broth cultures.
86
 The intracellular efficacy observed for 
fusidic acid and the analogues point to their ability to accumulate within phagocytic cells. 
This is consistent with existing literature reports of the intracellular efficacy of fusidic acid 
against several strains of S.aureus.
86,87
 
In an attempt to understand the disconnect between in vitro activity and in vivo efficacy of 
fusidic acid, the drug and its analogues (GKFA16, GKFA17, KSFA16, AW23 and AW25) 
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were screened for their metabolic stability in rodent and human liver microsomes and their 
resulting metabolites identified. The metabolism of fusidic acid has been shown to be species 
specific between rodents and humans, with the acyl glucuronide, 3-keto-, 27-carboxy- and 
hydroxylate being the main metabolites in man (Figure 18). These metabolites were shown to 
be less active than fusidic acid.
88
 
 
Figure 18: Fusidic acid metabolites in man.
88
 
However, fusidic acid is metabolized to 3-ketofusidic acid and 3-epifusidic acid in mouse 
liver microsomes (MLM, Figure 19). The main metabolite in MLM being the inactive 3-
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epifusidic acid, which is not observed in human liver microsomes (HLM).
89
 These 
metabolites have been found to have lower antibacterial activity than fusidic acid.
55
  
 
Figure 19: Fusidic acid metabolites in mouse liver microsomes (MLM) and human liver 
microsomes (HLM).
89
 
In rodent plasma, the fusidic acid is slowly hydrolysed at C-16 to a free alcohol, followed by 
lactonization with the acid moiety at C-21, to form a metabolite that is not observed in human 
plasma (Figure 20).
90
 
 
Figure 20: C-16 hydrolysis and lactonization of fusidic acid in rodent plasma.
90
 
Overall, the microsomal stability of these compounds was comparable across the three 
species (65% ± 5% remaining).
89
 It was observed that the C-3 esters, GKFA16 and 
GKFA17, were metabolized to fusidic acid in rat liver microsomes (RLM), suggesting that 
they act as prodrugs. The stability in plasma varied in the order of mouse >> rat > man, 
which is in agreement with literature reports.
89,91
 Moreover, both these C-3 esters were 
observed to be very stable in human plasma.
89
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As for the C-21 derivatives, only compound KSFA16 was metabolized to fusidic acid.
89
 The 
release of the sulfonyl hydrazide can be considered as a structural alert, since it is associated 
with organ toxicity.
92,93
 The C-21 amides AW23 and AW25 were not metabolized to fusidic 
acid, which may have contributed to their low in vitro activity.
86
  
The two prodrugs, GKFA16 and GKFA17, were then considered for further 
pharmacokinetic studies in a mouse model with the hypothesis that the lack of fusidic acid 
efficacy in mouse could be due to poor exposure of fusidic acid at the site of infection. 
Intravenous and oral administration of fusidic acid in mouse showed a higher level of the 3-
epifusidic acid metabolite than fusidic acid, suggesting that the low bioavailability was due to 
the inactive 3-epifusidic acid as opposed to low absorption. The metabolism of fusidic acid to 
the 3-epifusidic acid was observed to be gender specific, with a higher rate of metabolism in 
females rats compared to males.
94
  
Examination of the pharmacokinetic properties of selected compounds revealed that both 
GKFA16 and GKFA17 were metabolized to fusidic acid, with GKFA17 having a higher rate 
of clearance than GKFA16 and exposed the fusidic acid 3-hydroxy group to be further 
metabolized to 3-epifusidic acid (Table 3). Compound GKFA16 therefore sustained the 
concentrations of fusidic acid longer and acted as a slow metabolic activation compound. 
However, the final concentrations of fusidic acid remained low and unlikely to have any 
impact in the tuberculosis mouse model at a 20 mg/kg dosage.
94
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Table 3: In vivo pharmacokinetic results of C-3 esters in mouse model at 20 mg/kg dose.
94
 
 
R 
Fusidic acid 
 
GKFA16 
 
GKFA17 
 
Cl (ml/min/kg) 58.0 40.3 134 
t1/2 (hr) 1.80 1.19 1.63 
F (%) 12.4 43.5 44.5 
Fusidic acid AUC 
(min.uM/L) 
116 134 165 
Increase in fusidic 
acid AUC 
- 15.5 % 42.2 % 
Cl, clearance; t1/2, half-life; F, bioavailability; AUC, area-under-the curve 
In addition, it was observed that the 3-ketofusidic acid (GKFA37) had a higher rate of 
metabolism to 3-epifusidic acid when administered intravenously compared to oral 
administration. The metabolism from 3-ketofusidic acid to fusidic acid, on the other hand, 
was negligible.
94
 
Furthermore, compounds GKFA16 and GKFA17 were evaluated for their organ distribution 
as follows (i) in the lungs and spleen due to the high bacterial burden at these sites, (ii) liver 
and kidneys due to their role as elimination sites, and (iii) the heart and brain due to 
pericarditis and meningitis tuberculosis complications as well as the fact that fusidic acid is 
known to cross the blood brain barrier.
94,95
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Generally, the prodrug analogues showed improved organ distribution when compared to 
fusidic acid administration, resulting in a higher ratio of fusidic acid being observed in tissues 
than in blood.  
It is important to note that the presence of 3-epifusidic acid metabolite highlights the 
inappropriateness of the rodent models for fusidic acid in vivo evaluation. 
Further examples of fusidic acid derivatives that were synthesized in our research group 
include; C-21 bioisosteres which led to loss of antimycobacterial activity compared to fusidic 
acid, with most of the derivatives displaying MIC99 values ≥ 20 µM. However, a fusidic acid-
isoniazid conjugate showed respectable activity with MIC99 value of 10 µM. The decrease in 
antimycobacterial activity of C-21 derivatives suggests that the free carboxyl group is 
essential for activity (Figure 21).
85
  
The introduction of 3-epifusidic acid, carboxylic and silicate esters as well as oxime and keto 
functionalities at the C-3 position decreased the antimycobacterial activity (Figure 21). The in 
vitro antimycobacterial activity of 3-epifusidic acid suggests that the inversion of 
configuration at the C-3 position significantly reduces the antimycobacterial activity of 
fusidic acid derivatives.
85
  
Furthermore, C-16 derivatives were obtained by replacing the C-16 acetoxy group with 
methoxy and ethoxy groups, respectively, with the ethoxy derivative showing 
antimycobacterial activity comparable to fusidic acid.
85 A summary of the results obtained by 
the SAR performed in our laboratory is shown in Figure 21. 
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Figure 21: SAR summary of fusidic acid derivatives from our laboratory.
85
  
Inspired by the above information; this project has therefore focused on expanding the SAR 
studies previously explored, using bioisosterism and prodrug approaches.  
3.3 Design of fusidic acid derivatives  
3.3.1 Bioisosterism approach 
Bioisosteres are defined as atoms or group of atoms or molecules which may or may not have 
similar chemical and physical properties but their replacement produce broadly similar 
biological activity.
96
 Carboxylic acid groups are known to be responsible for a significant 
number of pharmacological drawbacks such as metabolic instability, toxicity and limited 
passive diffusion across biological membranes.
97
 Therefore, bioisosterism is used as an 
approach to optimize the biological activity of carboxylic acid containing drugs. Examples of 
carboxylic acid bioisosteres includes acyclic bioisosteres such as hydroxamic acid, 
acylsulfonamides, sulfonylureas, sulfonamides, sulphonic acid and cyclic bioisosteres such as 
tetrazole and oxadiazoles (Figure 22).
97
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Figure 22: Example of carboxylic acid bioisosteres 
Within the context of the bioisosterism approach, this study envisions introducing 
sulfonamide derivatives and sulfonyl hydrazide as bioisosteres of the carboxylic acid group 
of fusidic (Figure 23).  
3.3.2 Prodrug approach 
A prodrug is an inactive, bio-reversible derivative of an active drug molecule that can 
undergo in vivo enzymatic and/or chemical transformation to enable the bioactivation of the 
pharmacologically active parent drug at efficacious levels. The main objective of a prodrug 
design is to mask undesirable drug properties, such as low solubility, low target selectivity, 
metabolic instability, undesirable taste, irritation or pain after local administration, pre-
systemic metabolism and toxicity.
98–100
 
A prodrug approach is widely used in drug development programmes to improve on the 
physicochemical and/or pharmacokinetic properties of pharmacologically active compounds, 
through the optimization of absorption, distribution, metabolism, excretion, and toxicity 
(ADMET) properties.
98,100
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Therefore, the prodrug approach at the C-3 hydroxyl position was chosen to synthesize 
various fusidic acid ester derivatives based on the hypothesis that they will be metabolized to 
fusidic acid in vivo. The two C-3 open chain esters were resynthesized for comparison 
purposes, and to be used as a control in the screening of other test compounds (Figure 23).
85
  
Lastly, in an attempt to expand on the SAR exploration an amine derivative was included in 
the SAR strategy of this dissertation (Figure 23). 
 
Figure 23: Proposed antimycobacterial SAR study. 
To increase structural diversity and expand on the SAR of any lead compound, desired 
chemical and biological properties can be achieved by manipulating its physicochemical 
properties through the use of a Craig plot (Figure 24).
101
  A Craig plot predicts the correlation 
between physicochemical properties of a drug and its biological activity through a graph of 
hydrophobic character (π) of a substituent versus its electronic effect (Hammett substitution 
constant, σ).
101
 Therefore, to create structural diversity, the different substituents used in this 
study were selected from the Craig plot covering all four quadrants.
101
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Figure 24: Craig Plot.
101
  
3.4 Synthesis and characterization of fusidic acid derivatives  
3.4.1 Synthesis of C-21 derivatives (SAR 1) 
Scheme 1 shows the synthetic scheme for C-21 (SAR 1) derivatives of fusidic acid, using a 
procedure reported by Espinoza-Moraga, et. al.
102
 These target compounds were obtained via 
the coupling of fusidic acid (3.1) with the corresponding sulfonamide in the presence of 1-
ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI) as an activating agent and a catalytic 
amount of 4-dimethylaminopyridine (DMAP).
103
 The detailed synthetic procedure is 
described in Chapter 5. 
 
Scheme 1: General synthetic protocol towards compound 3.2 and 3.3 (SAR 1). Reagents and 
conditions: (a) p-X-C6H4SO2NH2, EDCI, DMAP, DCM, 25 °C, 3 days (3.2), 7 days (3.3). 
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The C-21 target compounds were obtained in extremely poor yields, summarized in Table 4, 
along with melting points. The poor yields can be attributed to the poor nucleophilicity of the 
sulfonamide reagent, as a result of the delocalization of the nitrogen non-bonding electron 
pair by the sulfone group. Starting material was largely recovered in these reactions, which 
did not go to completion. 
Table 4: Isolated yields and melting points of C-21 (SAR 1) derivatives and fusidic acid 
Compound Yield (%) Mp. (°C) 
3.1 - 187 – 189 
3.2 5 198 – 200 
3.3 3 219 – 221 
 
3.4.2 EDCI/DMAP-mediated amide coupling reaction mechanism  
The amide coupling reaction using EDCI and a catalytic amount of DMAP is believed to 
proceed through the formation of a reactive O-acylisourea intermediate, a product of a 
nucleophilic addition of the carboxylate ion to EDCI. DMAP is used to prevent 
rearrangement of the unstable O-acylisourea to N-acylurea via acyl transfer. The resulting 
acid-DMAP intermediate undergoes a nucleophilic attack by the amine to furnish the desired 
amide (Figure 25). This reaction is driven forward by the formation of a stable urea by-
product.
104,105
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Figure 25: Proposed reaction mechanism of EDCI/DMAP mediated amide coupling.
104,105
  
3.2.3 Characterization of target compounds 
All the fusidic acid analogues were characterized using 
1
H-NMR, 
13
C-NMR and mass 
spectroscopy (MS). For some of the synthesized compounds, 2D homonuclear correlation 
spectroscopy (COSY), heteronuclear single quantum correlation (HSQC), heteronuclear 
multiple bond correlation (HMBC) NMR experiments were acquired to aid in 
1
H-NMR and 
13
C-NMR assignments. The purity of all target compounds was checked using liquid 
chromatography-mass spectroscopy (LC-MS). 
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3.2.3.1 Characterization of fusidic acid (3.1) in CDCl3 
The 
1
H-NMR spectra of fusidic acid and its derivatives are complex, especially in the 
aliphatic region, due to the unsaturated ring systems. However, the characteristic 
1
H-NMR 
signals of fusidic acid (3.1, in CDCl3 at 400 MHz) appear at δ 5.87 (d, J = 8.4 Hz, H-16), 
5.08 (m, H-24), 4.33 (m, H-11), 3.75 (m, H-3), 3.04 (m, H-13), 1.95 (s, H-31), 1.66 (s, H-27), 
1.58 (s, H-26), 1.36 (s, H-30), 0.96 (s, H-19), 0.91 (d, J = 5.9 Hz, H-28) and 0.90 (s, H-18) 
ppm. The remaining proton signals appear in the aliphatic region δ 2.53-0.80 ppm (Figure 
26). Key 
1
H-
1
H COSY correlations are shown in appendix 1.  
 
Figure 26: 
1
H-NMR spectrum (CDCl3, 400 MHz) of fusidic acid (3.1) 
The 
13
C-NMR spectrum of fusidic acid (3.1) indicates 31 non-equivalent carbon signals. Six 
of these signals correspond to the two carbonyl carbons, C-21 at δ 174.0 ppm and C-29 at δ 
170.6 ppm and the other four carbon signals correspond to C-17, C-25, C-20 and C-24 
appearing at δ 150.8, 132.6, 129.6 and 123.0 ppm, respectively. The rest of the carbon signals 
appear in the aliphatic region δ 75-15 ppm, with the characteristic signals C-16, C-3 and C-
11, appearing at δ 74.4, 71.5, 68.3 ppm, respectively (Figure 27). This assignment of 
1
H- and 
13
C-NMR signals corresponds to those reported in literature.
106
 In addition, the mass 
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spectroscopy (MS) of fusidic acid (3.1) displays a mass peak of m/z 457.3 corresponding to 
[M-OAc]
+ 
and m/z 515.3 for [M-H]
-
. 
 
Figure 27: 
13
C-NMR spectrum (CDCl3, 100 MHz) of fusidic acid (3.1) 
3.2.3.2 Characterization of C-21 analogues 
The 
1
H-NMR and 
13
C-NMR spectra of the C-21 synthesized derivatives exhibit similar 
chemical shifts to those of fusidic acid (3.1), with additional signals corresponding to the 
respective attached sulfonamide moiety. Compound 3.2 is used here as a representative 
example for this set of target compounds.  
The 
1
H-NMR spectrum of compound 3.2 was recorded in DMSO-d6 at 400 MHz. The 
characteristic signals are the symmetrical aromatic signals appearing as doublets at δ 7.84 (d, 
J = 9.0 Hz, H-33/37) and 7.11 (d, J = 9.0 Hz, H-34/36) ppm. The appearance of two singlets 
at δ 11.75 (s, 1H, H-NH) and 3.83 (s, 3H, H-38) ppm corresponding to -CONH and H-38 
respectively, confirm the formation of an amide bond and therefore, the successful 
incorporation of the sulfonamide moiety into the fusidic acid structure (Figure 28). The 
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remaining proton signals appear in the region similar to that of fusidic acid. Stacked 
1
H-NMR 
spectra of compounds 3.1 and 3.2 are shown in appendix 2.  
 
Figure 28: 
1
H-NMR spectrum (DMSO-d6, 400 MHz) of compound 3.2 
The 
13
C-NMR spectrum of compound 3.2 revealed 35 carbon signals, with three of the 
signals accounting for two carbons each. The five additional signals correspond to the 
sulfonamide moiety, that is, C-32, C-33, C-34, C-35 and C-38, appearing at δ 163.0, 131.1, 
130.9, 114.2 and 55.7 ppm respectively. The defining carbon signal is the C-29 signal at δ 
169.7 ppm that has shifted downfield of the C-21 signal at δ 168.7 ppm (Figure 29). The 
remaining carbon signals appear in similar regions as those of fusidic acid. Moreover, a mass 
peak of m/z 626.2, corresponding to [M-OAc]
+ 
is observed for this compound, as expected. 
Thus, structure 3.2 was assigned to this compound. 
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Figure 29: 
13
C-NMR spectrum (DMSO-d6, 100 MHz) of compound 3.2 
3.2.4 Synthesis of C-3 fusidic acid derivatives (SAR 2) 
3.2.4.1 Synthesis of C-3 aliphatic esters and hydrazides 
The synthesis of target compounds 3.8 and 3.9 was achieved following the literature 
procedure reported by Kaur et al.,
103
 and Duvold et al.,
107
 (Scheme 2). The aliphatic ester 
intermediates 3.4 and 3.5 were synthesized via esterification of 3.1 with the respective acid or 
acid anhydride in pyridine. Compound 3.4 was obtained by the reaction of 3.1 with propanoic 
acid in pyridine in the presence of n-Propanephosphoric acid anhydride (T3P) as a coupling 
reagent. Compound 3.5 was obtained from the reaction of 3.1 with valeric acid anhydride in 
pyridine acting as a base and solvent (Scheme 2).  
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Scheme 2: General synthetic protocol towards compound 3.4 to 3.9 (SAR 2). Reagents and 
conditions: (a) valeric acid anhydride, pyridine, 25 
o
C, 3 h; (b) propanoic acid, T3P (50% w/v 
solution in DMF), pyridine, 0 
o
C – 25 
o
C, 17 h; (c) (i) EDCI, HOBt, CH3CN, 25 
o
C, 3 h, (ii) 
NH2NH2.H2O, 25 
o
C, 19 h (3.6) and 24 h (3.7); (d) MsCl, pyridine, 25 
o
C, 1 h (3.8) and 2 h 
(3.9). 
The fusidic acid hydrazides 3.6 and 3.7 were prepared by reacting 3-ester fusidic acid 3.4 or 
3.5 with hydrazine monohydrate in the presence of EDCI and HOBt in acetonitrile. The target 
compounds 3.8 and 3.9 were then obtained via a mesylation of the fusidic acid hydrazides 
with methanesulfonyl chloride (MsCl) in the presence of pyridine. Low to high isolated 
yields were obtained for these reactions as summarized in Table 5. 
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Table 5: Isolated yields and melting points of C-3 (SAR 2) aliphatic ester 
Compound Yield (%) Mp (°C) 
3.4 32 176 – 178 
3.5 45 155 – 157 
3.6 78 102 – 104 
3.7 58 86 – 88 
3.8 44 102 – 104 
3.9 54 103 – 105 
 
In these reactions, the C-3 hydroxyl was preferentially esterified, as the hydroxyl at C-11 is 
sterically hindered due to the chair-boat-chair conformation of fusidic acid (Figure 30). 
 
Figure 30: Chair-boat-chair conformation of fusidic acid. 
3.2.4.2  T3P-mediated reaction mechanism 
The reaction occurs via carboxylic acid activation through an attack of the carboxylate ion on 
the phosphorous atom of T3P. A nucleophilic attack on the activated  acid intermediate and a 
proton transfer leads to the formation of the desired ester (Figure 31).
108,109
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Figure 31: Proposed reaction mechanism for T3P-mediated coupling reaction.
108,109
 
3.2.4.3 Characterization of C-3 aliphatic ester analogues  
The 
1
H- and 
13
C-NMR spectra of these C-3 aliphatic esters can be described using 
intermediates 3.4, 3.6 and target compound 3.8 as illustrative examples. Stacked 
1
H-NMR 
spectra of compounds 3.1, 3.4, 3.6 and 3.8 are shown in appendix 3. 
3.2.4.3.1 Characterization of intermediate 3.4  
The 
1
H-NMR spectrum of intermediate 3.4 was recorded in CDCl3 at 400 MHz, with the 
distinct 
1
H-NMR spectral feature being the deshielded H-3 signal at δ 4.94 ppm from δ 3.75 
ppm (in 3.1). In addition, the structure is confirmed by the appearance of two new proton 
signals of H-2’ and H-3’, corresponding to the aliphatic chain at δ 2.35 ppm (q, J = 7.6 Hz) 
and δ 1.15 ppm (t, J = 7.6 Hz) respectively. The remaining proton signals appear in the 
similar region as that of 3.1 (Figure 32).   
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Figure 32: 
1
H-NMR spectrum (CDCl3, 400 MHz) of compound 3.4 
The 
13
C-NMR spectrum for compound 3.4 indicates the presence of characteristic signals 
which supports the presence of an ester group at δ 174.1 (C-1’) ppm. Furthermore, the 
downfield shift of the C-3 signal from δ 71.5 ppm in 3.1 to δ 74.0 ppm in 3.4 along with the 
appearance of the two ester side chain signals at δ 28.3 ppm (C-2’) and δ 9.6 ppm (C-3’), 
indicate a successful esterification reaction (Figure 33). A MS peak of m/z 513.3, 
corresponding to [M-OAc]
+
 further confirms the formation of intermediate 3.4. 
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Figure 33: 
13
C-NMR spectrum (CDCl3, 100 MHz) of compound 3.4 
3.2.4.3.2 Characterization of intermediate 3.6  
Intermediate 3.6 was obtained from the coupling of hydrazine monohydrate to intermediate 
3.4 with the 
1
H-NMR spectrum being recorded in CDCl3 at 400 MHz. In the 
1
H-NMR 
spectrum of 3.6, no evident change in chemical shifts is observed when compared to 3.4. For 
this reason, 
13
C-NMR and MS were used to confirm the success of the synthesis. 
In the 
13
C-NMR spectrum (Figure 34), the C-21 signal has shifted upfield from δ 174.3 ppm 
(in 3.4) to δ 171.9 ppm (in 3.6). The rest of the carbon signals appear in similar regions as in 
compound 3.4. The MS analysis of 3.6 reveals a m/z of 527.4 corresponding to [M-OAc]
+
, as 
expected.  
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Figure 34: 
13
C-NMR spectrum (CDCl3, 100 MHz) of compound 3.6 
3.2.4.3.3 Characterization of target compound 3.8  
Target compound 3.8 was obtained via mesylation of 3.6 with MsCl in pyridine. The 
characteristic features in the 
1
H-NMR spectrum of 3.8 (Figure 35) are the appearance of 
doublets in the aromatic region resonating at δ 7.82 ppm (J = 4.4 Hz) and 6.96 ppm (J = 4.5 
Hz) corresponding to –CONH and –SO2NH groups respectively. In addition, a H-32 signal at 
δ 2.97 ppm confirms the presence of the methyl group. The remaining proton signals appear 
in similar regions as in 3.6. 
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Figure 35: 
1
H-NMR spectrum (CDCl3, 400 MHz) of compound 3.8 
The 
13
C-NMR spectrum of 3.8 indicates 36 non-equivalent carbon signals (Figure 36). The 
presence of an additional carbon signal at δ 39.2 ppm (C-32) and the upfield shift of the C-21 
carbonyl carbon from δ 171.9 ppm (in 3.6) to δ 170.6 ppm (in 3.8) confirms the structure of 
target compound 3.8. Furthermore, a MS spectrum indicate a mass peak of m/z 605.3 
corresponding to [M-OAc]
+
 for this compound. 
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Figure 36: 
13
C-NMR spectrum (CDCl3, 100 MHz) of compound 3.8 
3.2.4.4 Synthesis of C-3 aromatic esters  
3.2.4.4.1 Synthesis of C-3 para substituted aromatic esters  
The synthesis of C-3 para substituted aromatic esters was performed according to a 
procedure reported by Xu et al.,
110
 via a Steglich esterification without any modification. This 
involved the addition of the respective aromatic acid to a mixture of compound 3.1, N,N-
dicyclohexylcarbodiimide (DCC) and DMAP in dry DCM (Scheme 3). The reactions were 
performed at 25 
o
C between 2–12 h. These C-3 esters were obtained in very low isolated 
yields (Table 6). 
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Scheme 3: General synthetic protocol towards compound 3.10 to 3.19 (SAR 2). Reagents 
and conditions: (a) p-X-C6H4COOH, DCC, DMAP, dry DCM, N2, 25 
o
C, 2-12 h. 
The very low yield is probably a result of the presence of both the carboxylic acid and 
alcohol functionalities in fusidic acid leading to an increase in competing side-reactions. 
Table 6: Isolated yields and melting points of SAR 2 aromatic esters  
Compound Yield (%) Mp (°C) Compound Yield (%) Mp (°C) 
3.10 10 172 – 174 3.15 14 135 – 137 
3.11 6 76 – 78 3.16 35 171 – 173 
3.12 13 118 – 120 3.17 39 177 – 179 
3.13 24 179 – 181 3.18 6 162 – 164 
3.14 13 161 – 163 3.19 12 166 – 168 
 
The 
1
H-NMR and 
13
C-NMR spectra of the para-substituted aromatic esters shows similar 
chemical shifts. Therefore, compound 3.13 is used here as an illustrative example for the 
characterization of this series of compounds. Stacked 
1
H-NMR spectra of compounds 3.1 and 
3.13 are shown in appendix 4. 
Chapter 3: Design, synthesis, characterization and biological evaluation of  
fusidic acid derivatives 
49 
 
3.2.4.4.2 Characterization of target compound 3.13  
The 
1
H-NMR spectrum of 3.13 was recorded in CD3OD at 400 MHz, with the characteristic 
signals being the new symmetric doublets resonating at δ 7.94 (J = 8.7 Hz, H-3’/7’) and 7.65 
(J = 8.7 Hz, H-4’/6’) ppm and the downfield shift of the key H-3 signal from δ 3.66 ppm in 
3.1 (in CD3OD, spectrum not shown) to δ 5.15 ppm. The remaining proton signals appeared 
in similar regions as in the starting material 3.1 (Figure 37).   
 
Figure 37: 
1
H-NMR spectrum (CD3OD, 400 MHz) of compound 3.13 
The 
13
C-NMR spectrum indicates 36 carbon signals, with two of the signals accounting for 
four carbons. The characteristic feature is the downfield shift of the C-3 signal from δ 72.4 in 
3.1 (in CD3OD, spectrum not shown) to δ 77.3 ppm in 3.13. In addition, the carbonyl carbon 
of the ester appears at δ 166.8 ppm (C-1’) while the aromatic carbon signals appear at δ 138.9 
(C-2’), 133.0 (C-3’), 132.1 (C-4’) and 131.2 (C-5’) ppm (Figure 38). The LC-MS of 3.13 
indicates a clear presence of isotopic bromine signals (m/z 697.3, 699.3) for [M-H]
-
. 
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Figure 38: 
13
C-NMR spectrum (CD3OD, 400 MHz) of compound 3.13 
3.2.4.4.3 Synthesis of C-3 heterocyclic esters  
The synthesis of C-3 heterocyclic esters was done similarly to para-substituted aromatic 
esters as reported by Xu et. al.,
110
 (Scheme 4). The synthesis of compound 3.21 resulted into 
a mixture of a mono-esterification product (3.21) and di-substituted ester (3.22) (Scheme 4). 
These reactions results in very low isolated yields of the products as summarized in Table 7. 
The low yields of these compounds can be explained by the same reasons indicated early for 
compounds 3.10-3.19. 
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Scheme 4: General synthetic protocol towards compound 3.20 to 3.22 (SAR 2). Reagents 
and conditions: (a) RCOOH, DCC, DMAP, dry DCM, N2, 25 
o
C, 2-12 h. 
Table 7: Isolated yields and melting points of SAR 2 heterocyclic esters 
Compound Yield (%) Mp (°C) 
3.20 11 184 – 186 
3.21 9 116 – 118 
3.22 12 134 – 136 
 
3.2.4.4.4 Characterization of C-3 heterocyclic aromatic esters 
The heterocyclic esters display closely related spectroscopic data. Thus compound 3.21 and 
3.22 are used as representative examples for this class of compounds. Stacked 
1
H-NMR 
spectra of compounds 3.1, 3.21 and 3.22 are shown in appendix 5. 
3.2.4.4.4.1 Characterization of compound 3.21  
The 
1
H-NMR spectrum of compound 3.21 was recorded in CD3OD at 400 MHz. The 
1
H-
NMR characteristic features of compound 3.21 include; a greatly deshielded signal of H-3 
from δ 3.66 in 3.1 (in CD3OD, spectrum not shown) to 5.30 ppm and the appearance of two 
new signals in the aromatic region at δ 9.30 (s, H-3’) and 8.82 (m, H-4’/5’) ppm (Figure 39). 
The rest of the proton signals appear in a similar region as in 3.1.  
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Figure 39: 
1
H-NMR spectrum (CD3OD, 400 MHz) of compound 3.21 
The characteristic signals from the 
13
C-NMR spectrum include, the extra carbonyl carbon at δ 
164.8 ppm corresponding to C-1’ and the downfield shift of the C-3 signal from δ 72.4 ppm 
in 3.1 (in CD3OD, spectrum not shown) to δ 78.8 ppm. Moreover, the carbon signals of the 2-
pyrazinecarboxylic moiety appear at δ 149.1 (C-5’), 146.8 (C-4’), 146.1 (C-3’) and 145.1 (C-
2’) ppm (Figure 40). A MS peak of m/z 621.4 for [M-H]
-
 further confirms the authenticity of 
compound 3.21. 
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Figure 40: 
13
C-NMR spectrum (CD3OD, 100 MHz) of compound 3.21 
3.2.4.4.4.2 Characterization of compound 3.22 
The 
1
H-NMR spectrum of compound 3.22 was recorded in CD3OD at 400 MHz. The 
characteristic features include the highly deshielded signals of H-3 resonating at δ 5.30 ppm 
from 3.66 (in 3.1, in CD3OD, spectrum not shown) and H-11 at δ 5.71 ppm from δ 4.32 in 3.1 
(in CD3OD, spectrum not shown). In addition, the aromatic proton signals are observed as 
follows; δ 9.18 (d, J = 1.2 Hz, H-3’), 9.06 (d, J = 1.4 Hz, H-8’), 8.80 (d, J = 2.4 Hz, H-5’), 
8.73 (dd, J = 2.5, 1.4 Hz, H-4’) and 8.70 (m, H-9’/10’) ppm (Figure 41). The rest of the 
proton signals appear in a similar region as in 3.1 and 3.21.  
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Figure 41: 
1
H-NMR spectrum (CD3OD, 400 MHz) of compound 3.22 
The 
13
C-NMR spectrum of compound 3.22  exhibits 40 distinct carbon signals, with four 
characteristic carbonyl signals at δ 173.7 (C-21), 172.4 (C-29), 164.8 (C-1’) and 164.5 (C-6’) 
ppm (Figure 42). Moreover, there is a downfield shift of C-3 from δ 72.4 in 3.1 (in CD3OD, 
spectrum not shown) to 78.1 ppm and C-11 from δ 68.6 in 3.1 (in CD3OD, spectrum not 
shown) to 74.4 ppm. The carbon signals of the two 2-pyrazinecarboxylic moieties appear at δ 
148.8 (C-5’), 147.23 (C-10’), 146.5 (C-4’), 146.3 (C-3’/8’), 146.2 (C-9’), 144.8 (C-2’) and 
144.7 (C-7’) ppm. The authenticity of 3.22 is further confirmed by the molecular ion peak 
with m/z ratio of 727.3, corresponding to [M-H]
-
. No significant change in chemical shifts for 
the rest of the carbon signals is observed. 
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Figure 42: 
13
C-NMR spectrum (CD3OD, 100 MHz) of compound 3.22 
3.2.5 Synthesis of C-3 amine (SAR 3) 
The synthetic route to intermediates 3.23 and 3.24 is similar to that used for intermediate 3.6 
and 3.8 previously (Scheme 2) as reported by Kaur et al.
103
 The synthesis of 3-ketofusidic 
acid (3.25) was accomplished via Jones oxidation as reported by Jursic et al.
111
 The Jones 
reagent was used as the limiting reagent to avoid oxidation occurring at both C-3 and C-11 
positions.  
Target compound 3.26 was obtained via reductive amination of 3.25 in 1,2-dichloroethane 
(DCE) with acetic acid as a catalyst and sodium triacetoxyhydroborate (Na(OAc)3BH) as a 
reducing agent (Scheme 5).
112,113
 Compound 3.26 was obtained as a 1:1 diastereoisomeric 
mixture. The isolated yields of these SAR 3 derivatives ranged from 12 to 90% (Table 8). 
The proposed reaction mechanism for the Jones oxidation and reductive amination are shown 
in Figures 43 and 44 respectively. 
 
Chapter 3: Design, synthesis, characterization and biological evaluation of  
fusidic acid derivatives 
56 
 
 
Scheme 5: General synthetic protocol towards compound 3.23 to 3.26 (SAR 3). Reagents 
and conditions: (a) (i) EDCI, HOBt, CH3CN, 25 °C, 3 h; (ii) NH2NH2.H2O, 25 °C, 24 h; 
(b) MsCl, pyridine, 25 °C, 3 h; (c) Jones Reagent, acetone, 0 °C, 40 min; (d) CH3NH2, 
Na(OAc)3BH, AcOH, DCE, 60 °C, 48 h . 
Table 8: Isolated yields and melting points of SAR 3 derivatives  
Compound Yield (%) Mp (°C) 
3.23 86 113 - 115 
3.24 90 125 – 127 
3.25 29 123 – 125 
3.26 12 137 – 139 
3.2.5.1 Mechanism of alcohol oxidation with chromic acid 
The mechanism of Jones oxidation involves the formation of chromic acid in the first step 
followed by formation of a chromate ester, which proceeds through an E2 elimination to 
afford the desired ketone (Figure 43).
114,115
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Figure 43: Proposed reaction mechanism for Jones oxidation.
114,115
 
3.2.5.2 Mechanism of reductive amination  
The first step of this reaction involves protonation and nucleophilic addition of the amine to 
the carbonyl carbon. This is followed by a proton transfer and elimination to produce an 
iminium ion. The iminium ion is then reduced by Na(OAc)3BH to afford the desired amine 
(Figure 44).
113,114,116
 
 
Figure 44: Proposed mechanism for reductive amination.
113,114,116
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3.2.5.3 Characterization of C-3 amine  
3.2.5.3.1 Characterization of intermediate 3.23  
The 
1
H-NMR spectrum of 3.23 was obtained in CD3OD at 400 MHz (Figure 45) and no 
significant change in proton chemical shifts is observed when compared to 3.1, as was 
previously observed for 3.6. Therefore, 
13
C-NMR and MS were used for structural 
confirmation. Stacked 
1
H-NMR spectra of compounds 3.1 and 3.24-26 are shown in appendix 
6. 
 
Figure 45: 
1
H-NMR spectrum (CD3OD, 400 MHz) of compound 3.23 
In the 
13
C-NMR spectrum, an upfield shift of the C-21 signal from δ 174.1 ppm in 3.1 (in 
CD3OD, spectrum not shown) to δ 173.1 ppm (in 3.23) is observed (Figure 46). Furthermore, 
a MS peak of m/z 529.3, corresponding to [M-H]
-
 is observed, as expected, which confirms 
the structure of 3.23.  
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Figure 46: 
13
C-NMR spectrum (CD3OD, 100 MHz) of compound 3.23 
3.2.5.3.2 Characterization of intermediate 3.24 
The 
1
H-NMR spectrum of 3.24 was recorded in CDCl3 at 400 MHz, with the characteristic 
features being the appearance of –CONH (δ 8.16 ppm, s) and –SO2NH (δ 7.10 ppm, br s) 
signals in the aromatic region. In addition, a new singlet in the aliphatic region at δ 3.00 ppm 
corresponding to H-32, confirms the presence of a methyl group (Figure 47). The rest of the 
proton signals appear in similar regions as in 3.1. 
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Figure 47: 
1
H-NMR spectrum (CDCl3, 400 MHz) of compound 3.24 
The 
1
H-NMR spectrum is supported by the appearance of an additional carbon signal at δ 
39.4 ppm, corresponding to C-32 (Figure 48). Furthermore, the MS spectrum displays a mass 
peak of m/z 549.3 corresponding to [M-OAc]
+
, as expected. The remaining carbon signals 
remain in similar regions as in intermediate 3.23. 
 
 
 
 
 
Chapter 3: Design, synthesis, characterization and biological evaluation of  
fusidic acid derivatives 
61 
 
 
Figure 48: 
13
C-NMR spectrum (CDCl3, 100 MHz) of compound 3.24 
3.2.5.3.3 Characterization of intermediate 3.25 
Intermediate 3.25 is a product of the Jones oxidation of 3.24 and the 
1
H-NMR characteristic 
feature is the absence of the key H-3 signal (Figure 49) that was previously observed at δ 
3.75 ppm in 3.24. The other distinctive feature is the downfield shift of the H-28 signal from 
δ 0.91 ppm (in 3.24) to δ 1.00 ppm in 3.25. The rest of the signals remain in similar regions 
as compared to 3.24. 
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Figure 49: 
1
H-NMR spectrum (CDCl3, 400 MHz) of compound 3.25 
A carbonyl characteristic signal of a ketone at δ 213.5 ppm (C-3) in the 
13
C-NMR spectrum 
and an upfield shift of the C-28 signal from δ 15.9 ppm (in 3.24) to δ 12.3 ppm (in 3.25) is 
evidence of the success of the Jones oxidation (Figure 50). Furthermore, a MS peak of m/z 
605.3 for [M-H]
-
 confirms the authenticity of intermediate 3.25.  
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Figure 50: 
13
C-NMR spectrum (CDCl3, 100 MHz) of compound 3.25 
3.2.5.3.4 Characterization of target compound 3.26  
The 
1
H-NMR characteristic features are the appearance of the new H-3 signal resonating at δ 
2.47 ppm and the H-1’ singlet at δ 2.37 ppm (Figure 51). 
 
Figure 51: 
1
H-NMR spectrum (CDCl3, 400 MHz) of compound 3.26. 
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The 
13
C-NMR spectrum of 3.26 indicates the loss of a carbonyl carbon at δ 213.5 ppm in 
intermediate 3.25 and the appearance of a carbon signal at δ 61.5 ppm, corresponding to C-3. 
In addition, the carbon signal of C-1’ at δ 35.0 ppm, confirms the success of the reductive 
amination reaction (Figure 52). A MS peak of m/z 620.3 for [M-H]
-
 is observed as expected. 
The configuration at the C-3 chiral center was not determined as the compound was obtained 
as a mixture of diastereoisomers as indicated earlier.   
 
Figure 52: 
13
C-NMR spectrum (CDCl3, 100 MHz) of compound 3.26 
3.3 Biological evaluation of target compounds 
All the synthesized target compounds and their intermediates were evaluated for their in vitro 
antimycobacterial activity against the human virulent H37Rv strain of Mtb using the 
microplate Alamar Blue assay (MABA) at the Institute of Infectious Disease and Molecular 
Medicine (IDM), University of Cape Town, South Africa. The reported MIC99 (minimum 
concentration that will inhibit 99% of the bacterial population) values at day 14, were 
performed in glycerol-alanine-salt with Tween-80 and iron (GAST/Fe) as well as in media 
comprising of bovine albumin, dextrose and catalase (7H9 GLU/ADC) with rifampicin as a 
control.  
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3.4.3 In vitro antimycobacterial activity  
The in vitro antimycobacterial activities for these compounds are summarized in Tables 9 
and 10. Upon observation of trends within different groups of compounds, neither of the four 
C-21 carboxylic acid bioisosteric analogues (3.2, 3.3, 3.23 and 3.24) exhibited comparable 
potency to fusidic acid (Table 9). This suggests that the carboxylic acid is essential for 
antimycobacterial activity, which is consistent with previous studies in our research group 
and the report by Duvold et al.
71
 It is interesting to note that although derivatization of the 
carboxylic acid resulted in loss of activity, compounds 3.2, 3.23 and 3.24 (MIC99 of 31.3 µM) 
displayed superior activity compared to analogue 3.3 (MIC99 of 125 µM). The in vitro 
antimycobacterial results indicate that almost all the tested compounds are inactive in the 
7H9 GLU/ADC media, except compounds 3.4 (MIC99 of 7.81 µM) and 3.5 (MIC99 of 3.91 
µM, Table 9). Due to the general lack of in vitro activity of the various derivatives in the 7H9 
GLU/ADC media, the following SAR discussion will be based on data generated in the 
GAST/Fe media. 
The two C-3 aliphatic esters 3.4 and 3.5 were previously synthesized in our research group
85
 
and were found to offer good activity, with both having MIC99 values of 2.5 µM in the same 
assays used at that time. Since good activity was observed with these two analogues, they 
were chosen as templates for further derivatization by incorporating carboxylic acid 
bioisosteres 3.6-3.9. For this set of derivatives 3.4-3.9, modification at both the C-3 and C-21 
positions appear to be detrimental to activity. The exception was the long chain aliphatic ester 
3.5, which was found to be equipotent to fusidic acid with a MIC99 value of 0.49 µM. 
Interestingly, incorporation of a mesyl group resulted in a 2-fold increase in 
antimycobacterial activity for 3.8 (MIC99 of 7.81 µM) compared to the 3.6 (MIC99 of 15.6 
µM). The rest of the tested compounds were deemed to have moderate to weak activity, with 
MIC99 values ranging between 15.6-62.5 µM. 
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The analogue aminated at C-3, which has a carboxylic acid bioisostere incorporated at the R1 
position (3.26), and its precursor intermediates (3.23-3.25) exhibited loss of 
antimycobacterial activity with moderate MIC99 values ranging between 31.3 to 62.5 µM 
(Table 9). In view of the good antimycobacterial activity of the 3-ketofusidic acid (MIC99 of 
1.25 µM, H37Rv),
85
 the activity displayed by compound 3.25 (MIC99 of 62.5 µM) in this 
study represents a significant loss in activity. This further supports the earlier observation that 
the carboxylic acid group at C-21 is essential for activity.
71,85
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Table 9: In vitro antimycobacterial activity at C-3 alkyl esters and C-21 bioisosteres of 
fusidic acid at day 14 
 
Compound R R1 
MIC99 (µM) 
GAST/Fe 7H9 GLU/ADC 
Fusidic acid   0.49 3.91 
3.2   
31.3 > 125 
3.3   
125 > 125 
3.4 
  
3.91 7.81 
3.5 
  
0.49 3.91 
3.6 
  
15.6 125 
3.7 
  
62.5 > 125 
3.8 
  
7.81 62.5 
3.9 
  
62.5 62.5 
3.23   31.3 > 125 
3.24  
 
31.3 > 125 
3.25  
 
62.5 > 125 
3.26   
31.3 > 125 
Rifampicin -  -  0.01 0.01 
 
On the other hand, the C-3 aromatic esters 3.10-3.22 were generally inactive (Table 10). 
However, introduction of substituents at the para position of the phenyl ring with groups 
such as methyl sulfonyl (3.17, MIC99 of 31.3 µM), methoxy (3.18, MIC99 of 62.5 µM) and 
methyl (3.19, MIC99 of 31.3 µM) groups led to a significant (2-4 fold) increase in 
antimycobacterial activity compared to the unsubstituted compound 3.10 (MIC99 of  >125 
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µM). The rest of the other para substituted phenyl derivatives 3.11-3.16 exhibited poor 
activity against Mtb H37Rv with MIC values of >125 µM.  
Heterocyclic-containing esters 3.20 and 3.21 (Table 10) showed superior activity compared 
to aromatic esters with pyrazinoic acid-based ester 3.21 showing activity in both media. It is 
hypothesized that this compound and its bis derivative 3.22 could release both fusidic acid 
and pyrazinoic acid upon hydrolysis by mycobacterial esterases. This would be a potential 
way of delivering pyrazinoic acid (POA), the active form of pyrazinamide, which requires the 
pyrazinamidase enzyme to release POA.   
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Table 10: In vitro antimycobacterial activity of C-3 aromatic ester derivatives of fusidic acid 
at day 14 
 
Compound R R1 
MIC99 (µM) 
GAST/Fe 7H9 GLU/ADC 
Fusidic acid   0.49 3.91 
3.10 
 
 > 125 > 125 
3.11 
 
 > 125 > 125 
3.12 
 
 > 125 > 125 
3.13 
 
 > 125 > 125 
3.14 
 
 > 125 > 125 
3.15 
 
 > 125 > 125 
3.16 
 
 > 125 125 
3.17 
 
 31.3 125 
3.18 
 
 62.5 > 125 
3.19 
 
 31.3 > 125 
3.20 
 
 31.3 > 125 
3.21 
 
 7.81 31.3 
3.22 
  
> 125 125 
Rifampicin -  - 0.01 0.01 
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3.5 Conclusion 
Based on prior SAR exploration executed in our research group, this dissertation has 
broadened the SAR study around fusidic acid at the C-3, C-11 and C-21 positions. To this 
end, 25 fusidic acid derivatives were successfully synthesized, characterized and evaluated 
for their in vitro antimycobacterial activity. None of these derivatives was found to possess 
superior in vitro antimycobacterial activity compared to fusidic acid although analogues 3.4, 
3.5, 3.8 and 3.21 were found to display good activity with MIC99 values ranging between 
0.49-7.81 µM in the GAST/Fe media. 
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CHAPTER 4 
Summary, conclusion and future work 
4.1 Summary and conclusion 
The broad aim of this project was to contribute to the repositioning of the antibacterial drug 
fusidic acid as a potential new antimycobacterial agent through a medicinal chemistry 
approach. The study was undertaken by executing various structural modifications on the 
fusidic acid scaffold at the C-3, C-11 and C-21 positions to broaden the SAR study. Standard 
organic synthetic routes such as amide coupling, esterification, Jones oxidation and reductive 
amination reactions were employed. Compounds were characterized by 
1
H-NMR, 
13
C-NMR, 
melting point and LC-MS. The synthesized target compounds and their respective 
intermediates were evaluated for their in vitro antimycobacterial activity against the H37Rv 
strain of Mtb. 
All the synthesized analogues were obtained in poor to good yields (3 – 90%), with the poor 
yields of some of the analogues possibly due to the difficulty in their chromatographic 
purification and competing side reactions. 
The antimycobacterial screening of fusidic acid analogues synthesized revealed a drop in 
activity with most analogues exhibiting MIC99 values of > 20 µM, except for compounds 3.4-
3.6, 3.8 and 3.21 (Figure 53). The new compounds 3.8 and 3.21 were the most potent 
compounds from this study with MIC99 values of 7.81 µM. The antimycobacterial activity 
data obtained suggests that the C-3 and C-11 hydroxyls, and C-21 carboxylic acid are 
essential for activity.  
Lastly, the lack of in vitro activity displayed by these analogues, except 3.4 (MIC99 of 7.81 
µM) and 3.5 (MIC99 of 3.91 µM), in the 7H9 GLU/ADC media suggests media-dependent 
activity.  
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Figure 53: Summary of fusidic acid derivatives with MIC99 < 20 µM in GAST/Fe media 
4.2 Future prospects 
The in vitro antimycobacterial data shown by compounds 3.4-3.6, 3.8 and 3.21 are 
encouraging. These compounds can be further explored for their cytotoxicity, microsomal 
metabolic stability and in vivo efficacy. To eradicate Mtb requires drug regimens that can 
penetrate multiple layers of complex pulmonary lesions; therefore, both intracellular and 
extracellular in vitro inhibition assays should be in the forefront of drug discovery and 
development for TB. 
The lack of in vitro activity displayed by 3.20-3.22 is not entirely clear but may be attributed 
to factors such as (i) poor penetration inside the bacteria; (ii) lack of Mtb-mediated hydrolysis 
of the prodrugs to their respective active metabolites under the assay conditions or (iii) high 
rate of efflux mechanisms. Therefore, it would be interesting to study the stability of these 
compounds when incubated with mycobacteria lysate in order to ascertain whether or not 
they are hydrolyzed.  
In addition, drugs like rifampicin and pyrazinamide have been shown to penetrate the cell 
well into necrotic caseum, the site of persisting tolerant mycobacteria that are responsible for 
drug resistance.
117
 As a result, 3.21 and 3.22 could potentially be evaluated as alternative 
prodrugs of pyrazinoic acid to circumvent PZA-resistant isolates of Mtb. 
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Moreover, further SAR exploration at the C-3 position of fusidic acid should be done through 
the introduction of  disubstitution in the phenyl ring or by varying the positions of 
substituents from para- to meta- or ortho- and by substituting the phenyl ring with various 
heterocyclic moieties (Figure 54).  
Based on the activity of C-3 amine 3.26, a diverse range of acyclic or heterocyclic amines 
should be investigated. 
 
Figure 54: Future recommendation to obtain new derivatives of fusidic acid. 
Lastly, fusidic acid and its derivatives have been previously shown to possess antiplasmodial 
activity against chloroquine-sensitive NF54 and multidrug-resistant K1 strains of the human 
malaria parasite Plasmodium falciparum. Therefore, this set of compounds should also be 
evaluated for antiplasmodial activity. 
Chapter 5: Experimental 
74 
 
CHAPTER 5 
Experimental 
5.1 Reagents, Solvents and Instruments 
Fusidic acid was purchased from AvaChem Scientific while all other reagents were 
purchased from Sigma-Aldrich, Merck or Combi-Blocks. These reagents were of analytical 
reagent (AR) grade and were used without further purification. Dry solvents were obtained 
from a SP-1 stand-alone solvent purification system, from LC Technology Solution Inc. The 
solvents used for HPLC and LC-MS were bought from Sigma-Aldrich (ammonium acetate as 
an additive), Merck (glacial acetic acid) and Microsep (acetonitrile and methanol) and were 
of HPLC grade. The general solvents used for extraction and purification purposes were 
obtained from Kimix Chemicals and were of AR grade. 
Reactions were monitored using aluminum silica pre-coated thin layer chromatography 
(TLC) plates (60 F254 from Merck or Al foils 60 Å medium pore diameter from Sigma-
Aldrich) and were visualized by ultraviolent light (UV) at 245 or 365 nm and by using p-
anisaldehyde stain. The stain solution was prepared by mixing solution A (5% p-anisaldehyde 
in EtOH) to B (5% H2SO4 and 20% AcOH in MeOH) in a 1:3 ratio. 
Purification of the compounds was done by gravity column chromatography packed with 
silica gel (60 Å, 70-230 mesh from Sigma-Aldrich) or by preparative TLC (Silica gel GF254, 
2000 µm on glass from Analtech). Melting points were determined using the Reichert-Jung 
Thermovar hot-stage microscope without correction. 
Reported compounds were characterized using MS, 
1
H NMR and 
13
C NMR. 
1
H NMR spectra 
were recorded on a Bruker UltraShield-Plus (400 MHz) spectrometer, with 
13
C NMR 
spectrum being recorded on the same instrument at 100 MHz, and referenced to the residual 
proton or carbon signals of the deuterated solvent with tetramethylsilane (TMS) as an internal 
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standard. NMR samples were dissolved in either deuterated chloroform (CDCl3), deuterated 
dimethyl sulfoxide (DMSO-d6) or deuterated methanol (CD3OD). Chemical shifts (δ) are 
reported in part per million (ppm) to two decimal place for 
1
H NMR and one decimal places 
for 
13
C NMR relative to TMS at 0 ppm. Coupling constants (J) are reported in Hertz (Hz) to 
one decimal place. 
1
H NMR splitting patterns are abbreviated as follows: s (singlet), broad 
singlet (br s), d (doublet), dd (doublet of doublets), t (triplet), q (quartet) and m (multiplet). 
The 
13
C NMR spectra were measured with complete proton decoupling. 
Liquid chromatography-mass spectrometric (LC-MS) data of all the compounds were 
determined on an Agilent HPLC system equipped with the following components: Agilent® 
1260 Infinity Binary Pump, Agilent® 1260 Infinity Diode Array Detector (DAD), Agilent® 
1290 Infinity Column Compartment, Agilent® 1260 Infinity Standard Auto sampler and 
Agilent® 6120 Quadrupole LC/MS. The column was a Kinetex Core C18 reverse phase 
column (2.6 µm particle, 3x50 mm and 100 Å). The column temperature was maintained at 
40.00 °C, with an injection volume of 2.0 µL. The mobile phase was made up of 10 mM 
ammonium acetate in water (A) and 10 mM ammonium acetate in methanol (B). The gradient 
mode was set to increase gradually to 100% A over 3 min and held constant for 1.5 min. The 
column was then re-equilibrated to initial mobile phase (80% B: 20% A) over 2.5 min. A 
flow rate of 0.900 mL/min and high pressure limit of 600.00 bars were maintained.  
The purity of the target compounds was determined using the diode array detector (DAD) 
with absorption wavelength range of 210-640 nm. MS spectra were obtained both by 
electrospray (ES, spray chamber conditions: gas temperature 310°C, vaporizer 210°C) and 
atmospheric pressure chemical ionization (APCI).  
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5.2 Synthesis and characterization 
5.2.1 Characterization of fusidic acid 
(Z)-2-((3R,4S,5S,8S,9S,10S,11R,13R,14S,16S)-16-acetoxy-3,11-dihydroxy-4,8,10,14-
tetramethylhexadecahydro-17H-cyclopenta[a]phenanthren-17-ylidene)-6-methylhept-5-
enoic acid, [3.1]  
 
White solid: m.p. 187 - 189 °C; Rf  0.31 (MeOH:DCM, 0.6:9.4); 
1
H NMR (400 MHz, CDCl3) 
δH 5.87 (d, J = 8.4 Hz, 1H, H
16
), 5.12 – 5.05 (m, 1H, H
24
), 4.36 – 4.31 (m, 1H, H
11
), 3.77 – 
3.72 (m, 1H, H
3
), 3.09 – 3.00 (m, 1H, H
13
), 2.51 – 2.38 (m, 2H, H
22
), 2.34 – 2.28 (m, 1H, 
H
12a
), 2.21 – 1.99 (m, 5H, H
1a,5,15a,23
), 1.95 (s, 3H, H
31
), 1.90 – 1.78 (m, 2H, H
2a,12b
), 1.77 – 
1.69 (m, 2H, H
2b,7a
), 1.66 (s, 3H, H
27
), 1.58 (s, 3H, H
26
), 1.57 – 1.45 (m, 4H, H
1b,4,6a,9
), 1.36 
(s, 3H, H
30
), 1.29 (d, J = 14.1 Hz, 1H, H
15b
), 1.17 – 1.02 (m, 2H, H
6b,7b
), 0.96 (s, 3H, H
19
), 
0.91 (d, J = 5.9 Hz, 3H, H
28
), 0.90 (s, 3H, H
18
); 
13
C NMR (100 MHz, CDCl3) δC 174.0, 170.6, 
150.8, 132.6, 129.6, 123.0, 74.4, 71.5, 68.3, 49.3, 48.7, 44.3, 39.5, 39.0, 37.0, 36.3, 36.1, 
35.6, 32.3, 30.2, 29.9, 28.8, 28.4, 25.7, 24.1, 22.8, 20.8, 20.6, 17.9, 17.8, 15.9; purity (LC-
MS) 99%, tR = 5.25 min, MS m/z 457.3 [M-OAc]
+
; m/z 515.3 [M-H]
-
. 
5.2.2 General procedure for the synthesis and characterization of C-21 bioisosters 
Fusidic acid (1.0 eq.) was added to a solution of the respective sulfonamide (4.0 eq. for 
compound 3.2 and 1.2 eq. for compound 3.3) in dichloromethane (DCM) followed by a 
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subsequent addition of EDCI (1.4 eq.) and DMAP (0.4 eq.). The resulting mixture was stirred 
at 25 °C for 3 to 7 days. After completion of reaction (TLC), the reaction mixture was diluted 
with DCM and washed with water. The organic layer was dried over anhydrous magnesium 
sulfate (MgSO4), filtered and concentrated in vacuo. The crude product was then purified by 
column chromatography on silica gel using either EtOAc/DCM or MeOH/DCM as an eluent, 
which after washing with pentane and recrystallization in pentane/DCM afforded the desired 
target compound. 
(3R,4S,5S,8S,9S,10S,11R,13R,14S,16S,Z)-17-(1-((4-cyanophenyl)sulfonamido)-6-methyl-
1-oxohept-5-en-2-ylidene)-3,11-dihydroxy-4,8,10,14-tetramethylhexadecahydro-1H-
cyclopenta[a]phenanthren-16-yl acetate, [3.2] 
 
White solid (15 mg, 5% yield); m.p. 198 - 200 °C; Rf  0.39 (MeOH:DCM, 0.7:9.3); 
1
H NMR 
(400 MHz, DMSO-d6) δH 11.75 (s, 1H, H
NH
), 7.84 (d, J = 9.0 Hz, 2H, H
33/37
), 7.11 (d, J = 9.0 
Hz, 2H, H
34/36
), 5.58 (d, J = 8.6 Hz, 1H, H
16
), 4.95 – 4.89 (m, 1H, H
24
), 4.19 – 4.10 (m, 1H, 
H
11
), 3.83 (s, 3H, H
38
), 3.56 – 3.46 (m, 1H, H
3
), 2.92 – 2.83 (m, 1H, H
13
), 2.40 – 2.20 (m, 3H, 
H
12a,22
), 2.15 – 1.90 (m, 5H, H
1a,5,15a,23
), 1.78 (s, 3H, H
31
), 1.75 – 1.58 (m, 4H, H
2,7a,12b
), 1.56 
(s, 3H, H
27
), 1.52 – 1.33 (m, 4H, H
1b,4,6a,9
), 1.31 (s, 3H, H
26
), 1.27 (s, 3H, H
30
), 1.10 (d, J = 
13.9 Hz, 1H, H
15b
), 1.07 – 0.93 (m, 2H, H
6b,7b
), 0.88 (s, 3H, H
19
), 0.80 (s, 3H, H
18
), 0.79 (d, J 
= 7.2 Hz, 3H, H
28
); 
13
C NMR (100 MHz, DMSO-d6) δC 169.7, 168.7, 163.0, 144.6, 131.4, 
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131.1, 130.9 (2C), 129.9, 122.9, 114.0 (2C), 73.1, 69.2, 65.7, 55.7, 48.6, 48.0, 42.9, 38.8, 
38.7, 36.3 (2C), 35.8, 35.1, 31.7, 30.2, 29.4, 28.7, 26.7, 25.2, 23.3, 22.8, 20.7, 20.4, 17.4, 
17.2, 16.2; purity (LC-MS) 99%, tR = 5.19 min, MS m/z 626.2 [M-OAc]
+
. 
(3R,4S,5S,8S,9S,10S,11R,13R,14S,16S,Z)-3,11-dihydroxy-17-(1-((4-methoxyphenyl) 
sulfonamido)-6-methyl-1-oxohept-5-en-2-ylidene)-4,8,10,14-tetramethylhexadecahydro-
1H-cyclopenta[a]phenanthren-16-yl acetate, [3.3] 
 
White solid (20 mg, 3% yield); m.p. 219 – 221 °C; Rf  0.24 (EtOAc:Hex, 8:2);  
1
H NMR (400 
MHz, DMSO-d6) δH 12.24 (s, 1H, H
NH
), 8.12 (d, J = 8.5 Hz, 2H, H
33/37
), 8.06 (d, J = 8.5 Hz, 
2H, H
34/36
), 5.59 (d, J = 8.4 Hz, 1H, H
16
), 4.98 – 4.85 (m, 1H, H
24
), 4.18 – 4.02 (m, 1H, H
11
), 
3.55 – 3.46 (m, 1H, H
3
), 2.93 – 2.82 (m, 1H, H
13
), 2.42 – 2.19 (m, 3H, H
12a,22
), 2.19 – 1.89 
(m, 5H, H
1a,5,15a,23
), 1.80 (s, 3H, H
31
), 1.76 – 1.57 (m, 4H, H
2,7a,12b
), 1.55 (s, 3H
27
), 1.51 – 1.31 
(m, 4H, H
1b,4,6a,9
), 1.29 (s, 3H, H
26
), 1.27 (s, 3H, H
30
), 1.11 (d, J = 14.0 Hz, 1H, H
15b
), 1.07 – 
0.94 (m, 2H, H
6b,7b
), 0.87 (s, 3H, H
19
), 0.80 (s, 3H, H
18
), 0.78 (d, J = 7.1 Hz, 3H, H
28
); 
13
C 
NMR (100 MHz, DMSO-d6) δC 169.7 (2C), 144.0, 133.1, 132.2 (2C), 131.6, 128.3 (2C), 
127.0, 122.8, 117.5, 117.4, 73.1, 69.2, 65.7, 48.6, 48.0, 43.1, 39.5, 38.7, 36.3 (2C), 35.8, 35.1, 
31.7, 30.2, 29.4, 28.6, 26.8, 25.2, 23.4, 22.8, 20.7, 20.5, 17.4, 17.2, 16.2; purity (LC-MS) 
95%, tR = 5.04 min, MS m/z 621.2 [M-OAc]
+
. 
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5.2.3 Procedures for the synthesis and characterization of C-3 aliphatic esters  
5.2.3.1 Intermediates 3.4 and 3.5 
(Z)-2-((3R,4S,5S,8S,9S,10S,11R,13R,14S,16S)-16-acetoxy-11-hydroxy-4,8,10,14-
tetramethyl-3-(propionyloxy)hexadecahydro-17H-cyclopenta[a]phenanthren-17-
ylidene)-6-methylhept-5-enoic acid, [3.4] 
 
To a mixture of fusidic acid (3.78 g, 7.32 mmol) and propanoic acid (0.60 mL, 8.05 mmol, d 
= 0.993 g/mL) in pyridine (4.00 mL), T3P solution (4.27 ml, 50% w/v in DMF, density = 1.09 
g/mL, 14.63 mmol) was added and the resulting reaction mixture was stirred in an ice bath 
for 3 hrs. and at 25 °C for 21 hrs. After completion of the reaction (TLC), the reaction 
mixture was diluted with EtOAc (30 mL), washed with 0.5 M aq. HCl (3×30 mL) and water 
(3×30 mL). The organic layer was dried over anhydrous MgSO4, filtered and concentrated in 
vacuo. The crude product was then purified by column chromatography on silica gel using 
50% EtOAc/DCM as eluent, which after washing with pentane afforded white solid (1.32 g, 
32% yield); m.p. 176 – 178 °C; Rf 0.42 (EtOAc:DCM, 3:7); 
1
H NMR (400 MHz, CDCl3) δH 
5.89 (d, J = 8.4 Hz, 1H, H
16
), 5.14 – 5.04 (m, 1H, H
24
), 4.97 – 4.90 (m, 1H, H
3
), 4.37 – 4.29 
(m, 1H, H
11
), 3.09 – 2.99 (m, 1H, H
13
), 2.52 – 2.41 (m, 2H, H
22
), 2.35 (q, J = 7.6 Hz, 2H, 
H
2’
), 2.33 – 2.27 (m, 1H, H
12a
), 2.22 – 2.00 (m, 5H, H
1a,5,15a,23
), 1.96 (s, 3H, H
31
), 1.91 – 1.74 
(m, 4H, H
2,7a,12b
), 1.73 – 1.67 (m, 1H, H
4
), 1.67 (s, 3H, H
27
), 1.59 (s, 3H, H
26
), 1.58 – 1.49 (m, 
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3H, H
1b,6a,9
), 1.37 (s, 3H, H
30
), 1.32 (d, J = 14.2 Hz, 1H, H
15b
), 1.15 (t, J = 7.6 Hz, 3H, H
3’
), 
1.13 – 1.01 (m, 2H, H
6b,7b
), 0.98 (s, 3H, H
19
), 0.91 (s, 3H, H
18
), 0.81 (d, J = 6.7 Hz, 3H, H
28
); 
13
C NMR (100 MHz, CDCl3) δC 174.3, 174.1, 170.7, 151.3, 132.8, 129.7, 123.1, 74.6, 74.0, 
68.4, 49.3, 49.0, 44.5, 39.6, 39.2, 38.0, 37.1, 35.9, 35.0, 33.0, 31.2, 28.9, 28.5, 28.3, 27.6, 
25.9, 24.5, 22.7, 20.8, 20.7, 18.2, 17.9, 15.7, 9.6; purity (LC-MS) 98%, tR = 5.63 min, MS m/z 
513.3 [M-OAc]
+
. 
(Z)-2-((3R,4S,5S,8S,9S,10S,11R,13R,14S,16S)-16-acetoxy-11-hydroxy-4,8,10,14-
tetramethyl-3-(pentanoyloxy)hexadecahydro-17H-cyclopenta[a]phenanthren-17-
ylidene)-6-methylhept-5-enoic acid, [3.5] 
 
Valeric anhydride (7.20 mL, 36.74 mmol) was added to a solution of fusidic acid (3.45 g, 
6.68 mmol) in pyridine (3.50 mL) and stirred at 25 °C for 6 hrs. After completion of reaction 
(TLC), the reaction mixture was diluted with DCM (30 mL) and washed with water (3×30 
mL). The organic layer was dried over anhydrous MgSO4, filtered and concentrated in vacuo. 
The crude product was then purified by column chromatography on silica gel using 4% 
MeOH/DCM as eluent, which after pentane wash afforded white solid (1.79 g, 45% yield); 
m.p. 155 – 157 °C; Rf  0.40 (EtOAc:DCM, 3:7); 
1
H NMR (400 MHz, CDCl3) δH 5.89 (d, J = 
8.3 Hz, 1H, H
16
), 5.15 – 5.05 (m, 1H, H
24
), 4.97 – 4.90 (m, 1H, H
3
), 4.37 – 4.29 (m, 1H, H
11
), 
3.13 – 2.99 (m, 1H, H
13
), 2.50 – 2.42 (m, 2H, H
22
), 2.32 (d, J = 7.5 Hz, 2H, H
2’
), 2.30 – 2.27 
Chapter 5: Experimental 
81 
 
(m, 1H, H
12a
), 2.21 – 2.00 (m, 5H, H
1a,5,15a,23
), 1.95 (s, 3H, H
31
), 1.90 – 1.74 (m, 4H, H
2,7a,12b
), 
1.66 (s, 3H, H
27
), 1.64 – 1.61 (m, 1H, H
4
), 1.59 (s, 3H, H
26
), 1.60 – 1.49 (m, 5H, H
1b,3’,6a,9
), 
1.37 (s, 3H, H
30
), 1.36 – 1.34 (m, 2H, H
4’
), 1.32 (d, J = 14.2 Hz, 1H, H
15b
), 1.18 – 1.01 (m, 
2H, H
6b,7b
), 0.98 (s, 3H, H
19
), 0.91 (s, 3H, H
18
), 0.91 (t, J = 7.3 Hz, 3H, H
5’
), 0.81 (d, J = 6.7 
Hz, 3H, H
28
); 
13
C NMR (100 MHz, CDCl3) δC 174.3, 173.7, 170.6, 151.3, 132.8, 129.7, 
123.2, 74.6, 74.0, 68.4, 49.3, 49.0, 44.5, 39.6, 39.2, 38.0, 37.1, 35.9, 35.0, 34.7, 33.0, 31.2, 
28.9, 28.5, 27.6, 27.5, 25.8, 24.5, 22.7, 22.5, 20.7, 20.7, 18.2, 17.9, 15.8, 13.9; purity (LC-
MS) 98%, tR = 5.69 min, MS m/z 541.4 [M-OAc]
+
. 
5.2.3.2 Intermediates 3.6 and 3.7 
To a solution of compound 3.4 or 3.5 (1.0 eq.) in acetonitrile, HOBt (1.0 eq.) and EDCI (1.0 
eq.) were added and the resulting mixture was stirred for 3 hrs. at 25 °C. Hydrazine 
monohydrate (4.0 eq.) was then added after which the reaction mixture was and stirred 
further for 19 to 24 hrs. After completion of reaction (TLC), the reaction mixture was 
concentrated under reduced pressure and the resulting residue was taken up in ethyl acetate. 
The resulting solution was then washed with water, dried over anhydrous MgSO4, filtered 
and concentrated in vacuo. The crude product was then purified by column chromatography 
on silica gel, which after pentane wash afforded the desired product. 
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(3R,4S,5S,8S,9S,10S,11R,13R,14S,16S,Z)-16-acetoxy-17-(1-hydrazinyl-6-methyl-1-
oxohept-5-en-2-ylidene)-11-hydroxy-4,8,10,14-tetramethylhexadecahydro-1H-
cyclopenta[a]phenanthren-3-yl propionate, [3.6] 
 
White solid (536 mg, 78% yield); m.p. 102 – 104 °C; Rf  0.36 (EtOAc:DCM, 3:2);
 1
H NMR 
(400 MHz, CDCl3) δH 5.78 (d, J = 8.2 Hz, 1H, H
16
), 5.09 – 5.02 (m, 1H, H
24
), 4.96 – 4.90 (m, 
1H, H
3
), 4.34 – 4.27 (m, 1H, H
11
), 3.02 – 2.92 (m, 1H, H
13
), 2.51 – 2.40 (m, 1H, H
22a
), 2.34 
(q, J = 7.6 Hz, 2H, H
2’
), 2.29 – 2.22 (m, 2H, H
12a,22b
), 2.15 – 2.03 (m, 5H, H
1a,5,15a,23
), 2.02 (s, 
3H, H
31
), 1.86 – 1.74 (m, 4H, H
2,7a,12b
), 1.73 – 1.68 (m, 1H, H
4
), 1.67 (s, 3H, H
27
), 1.59 (s, 
3H, H
26
), 1.58 – 1.48 (m, 3H, H
1b,6a,9
), 1.35 (s, 3H, H
30
), 1.26 (d, J = 14.3 Hz, 1H, H
15b
), 1.14 
(t, J = 7.6 Hz, 3H, H
3’
), 1.11 – 0.99 (m, 2H, H
6b,7b
), 0.97 (s, 3H, H
19
), 0.94 (s, 3H, H
18
), 0.81 
(d, J = 6.7 Hz, 3H, H
28
); 
13
C NMR (100 MHz, CDCl3) δC 174.2, 171.9, 170.8, 143.9, 134.0, 
132.8, 123.2, 74.0, 73.6, 68.4, 49.3, 49.0, 43.6, 39.7, 39.5, 38.1, 37.2, 35.9, 34.9, 33.1, 31.3, 
29.5, 28.3, 28.0, 27.5, 25.9, 24.5, 22.6, 21.3, 20.7, 18.1, 18.0, 15.7, 9.5; purity (LC-MS) 90%, 
tR = 5.53 min, MS m/z 527.4 [M-OAc]
+
. 
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(3R,4S,5S,8S,9S,10S,11R,13R,14S,16S,Z)-16-acetoxy-17-(1-hydrazinyl-6-methyl-1-
oxohept-5-en-2-ylidene)-11-hydroxy-4,8,10,14-tetramethylhexadecahydro-1H-
cyclopenta[a]phenanthren-3-yl pentanoate, [3.7] 
 
White solid (615 mg, 58% yield); m.p. 86 – 88 °C; Rf  0.33 (EtOAc:DCM, 3:2);
 1
H NMR (400 
MHz, CDCl3) δH 5.78 (d, J = 8.3 Hz, 1H, H
16
), 5.10 – 5.01 (m, 1H, H
24
), 4.97 – 4.89 (m, 1H, 
H
3
), 4.36 – 4.27 (m, 1H, H
11
), 3.04 – 2.94 (m, 1H, H
13
), 2.51 – 2.40 (m, 1H, H
22a
), 2.32 (t, J = 
7.4 Hz, 2H, H
2’
), 2.29 – 2.22 (m, 2H, H
12a,22b
), 2.16 – 2.04 (m, 5H, H
1a,5,15a,23
), 2.02 (s, 3H, 
H
31
), 1.88 – 1.74 (m, 4H, H
2,7a,12b
), 1.67 (s, 3H, H
27
), 1.64 – 1.60 (m, 1H, H
4
), 1.59 (s, 3H, 
H
26
), 1.58 – 1.49 (m, 5H, H
1b,3’,6a,9
), 1.36 (s, 3H, H
30
), 1.41 – 1.30 (m, 2H, H
4’
), 1.27 (d, J = 
14.2 Hz, 1H, H
15b
), 1.18 – 1.00 (m, 2H, H
6b,7b
), 0.97 (s, 3H, H
19
), 0.94 (s, 3H, H
18
), 0.91 (t, J 
= 7.3 Hz, 3H, H
5’
), 0.81 (d, J = 6.7 Hz, 3H, H
28
); 
13
C NMR (100 MHz, CDCl3) δC 173.6, 
171.9, 170.8, 143.9, 134.0, 132.8, 123.2, 74.0, 73.6, 68.4, 49.3, 49.0, 43.6, 39.7, 39.5, 38.1, 
37.2, 35.9, 34.9, 34.7, 33.1, 31.3, 29.5, 28.0, 27.6, 27.5, 25.9, 24.5, 22.6, 22.5, 21.3, 20.7, 
18.1, 18.0, 15.8, 13.9; purity (LC-MS) 93%, tR = 5.82 min, MS m/z 555.4 [M-OAc]
+
. 
5.2.3.3 Target compound 3.8 and 3.9  
Methanesulfonyl chloride (1.0 eq.) was added to a solution of compound 3.6 or 3.7 (1.0 eq.) 
in pyridine with stirring at 25 °C for 2 hrs. After completion of reaction (TLC), the reaction 
mixture was diluted with ethyl acetate and washed with water and 0.5 M aq. HCl. The 
Chapter 5: Experimental 
84 
 
organic layer was dried over anhydrous MgSO4, filtered and concentrated in vacuo to afford 
the crude product which was purified by column chromatography on silica gel using 
EtOAc/DCM as eluent. The resulting oil was washed with pentane to afford the target 
compound. 
(3R,4S,5S,8S,9S,10S,11R,13R,14S,16S,Z)-16-acetoxy-11-hydroxy-4,8,10,14-tetramethyl-
17-(6-methyl-1-(2-(methylsulfonyl)hydrazinyl)-1-oxohept-5-en-2-
ylidene)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl propionate, [3.8] 
 
White solid (181 mg, 44% yield); m.p. 102 – 104 °C; Rf  0.50 (EtOAc:DCM, 3:7);
 1
H NMR 
(400 MHz, CDCl3) δH 7.82 (d, J = 4.4 Hz, 1H, H
CONH
), 6.96 (d, J = 4.5 Hz, 1H, H
SO
2
NH
), 5.72 
(d, J = 8.1 Hz, 1H, H
16
), 5.13 – 5.05 (m, 1H, H
24
), 4.95 – 4.89 (m, 1H, H
3
), 4.34 – 4.27 (m, 
1H, H
11
), 3.06 – 2.99 (m, 1H, H
13
), 2.97 (s, 3H, H
32
), 2.52 – 2.43 (m, 1H, H
22a
), 2.33 (q, J = 
7.6 Hz, 2H, H
2’
), 2.31 – 2.22 (m, 2H, H
12a,22b
), 2.20 – 2.01 (m, 5H, H
1a,5,15a,23
), 1.99 (s, 3H, 
H
31
), 1.87 – 1.74 (m, 4H, H
2,7a,12b
), 1.73 – 1.67 (m, 1H, H
4
), 1.67 (s, 3H, H
27
), 1.59 (s, 3H, 
H
26
), 1.58 – 1.49 (m, 3H, H
1b,6a,9
), 1.35 (s, 3H, H
30
), 1.30 (d, J = 14.3 Hz, 1H, H
15b
), 1.14 (t, J 
= 7.6 Hz, 3H, H
3’
), 1.13 – 1.00 (m, 2H, H
6b,7b
), 0.97 (s, 3H, H
19
), 0.93 (s, 3H, H
18
), 0.80 (d, J 
= 6.7 Hz, 1H, H
28
); 
13
C NMR (100 MHz, CDCl3) δC 174.0, 170.6 (2C), 146.4, 133.3, 131.9, 
122.6, 73.9, 73.8, 68.2, 49.1, 48.9, 43.8, 39.5, 39.3, 39.1, 37.9, 37.0, 35.7, 34.7, 32.9, 31.1, 
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29.7, 28.2, 28.1, 27.4, 25.7, 24.3, 22.4, 21.1, 20.4, 18.2, 17.8, 15.6, 9.4; purity (LC-MS) 96%, 
tR = 5.52 min, MS m/z 605.3 [M-OAc]
+
. 
(3R,4S,5S,8S,9S,10S,11R,13R,14S,16S,Z)-16-acetoxy-11-hydroxy-4,8,10,14-tetramethyl-
17-(6-methyl-1-(2-(methylsulfonyl)hydrazinyl)-1-oxohept-5-en-2-
ylidene)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl pentanoate, [3.9] 
 
White solid (262 mg, 54% yield); m.p. 103 – 105 °C; Rf  0.38 (EtOAc:DCM, 1:9); 
1
H NMR 
(400 MHz, CDCl3) δH 7.82 (d, J = 3.9 Hz, 1H, H
CONH
), 6.94 (d, J = 3.9 Hz, 1H, H
SO
2
NH
), 5.73 
(d, J = 8.0 Hz, 1H, H
16
), 5.14 – 5.05 (m, 1H, H
24
), 4.96 – 4.89 (m, 1H, H
3
), 4.38 – 4.27 (m, 
1H, H
11
), 3.08 – 3.01 (m, 1H, H
13
), 2.98 (s, 3H, H
32
), 2.54 – 2.43 (m, 1H, H
22a
), 2.32 (t, J = 
7.5 Hz, 2H, H
2’
), 2.30 – 2.22 (m, 2H, H
12a,22b
), 2.20 – 2.02 (m, 5H, H
1a,5,15a,23
), 2.00 (s, 3H, 
H
31
), 1.89 – 1.75 (m, 4H, H
2,7a,12b
), 1.68 (s, 3H, H
27
), 1.67 – 1.62 (m, 1H, H
4
), 1.61 (s, 3H, 
H
26
), 1.60 – 1.49 (m, 5H, H
1b,3’,6a,9
), 1.36 (s, 3H, H
30
), 1.41 – 1.32 (m, 2H, H
4’
), 1.32 (d, J = 
14.3 Hz, 1H, H
15b
), 1.19 – 1.01 (m, 2H, H
6b,7b
), 0.98 (s, 3H, H
19
), 0.94 (s, 3H, H
18
), 0.91 (t, J 
= 7.3 Hz, 3H, H
5’
), 0.81 (d, J = 6.5 Hz, 3H, H
28
); 
13
C NMR (100 MHz, CDCl3) δC 173.6, 
170.8, 170.7, 146.7, 133.5, 132.0, 122.8, 74.1, 74.0, 68.4, 49.3, 49.1, 44.0, 39.7, 39.5, 39.2, 
38.1, 37.2, 35.8, 34.8, 34.7, 33.1, 31.3, 29.9, 28.4, 27.6, 27.5, 25.9, 24.5, 22.6, 22.5, 21.3, 
20.6, 18.4, 18.0, 15.8, 13.9; purity (LC-MS) 97%, tR = 5.73 min, MS m/z 633.4 [M-OAc]
+
. 
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5.2.4 General procedure for the synthesis and characterization of C-3 aromatic esters  
The respective carboxylic acid (4.0 eq.), DCC (4.0 eq.) and DMAP (0.4 eq.) were added to a 
solution of fusidic acid (1.0 eq.) in anhydrous DCM. The reaction mixture was stirred at 25 
°C under N2 atmosphere. After completion of reaction (TLC), the reaction mixture was 
diluted with ethyl acetate, filtered and washed with 2 N HCl, saturated aq. NaHCO3, brine and 
water. The organic layer was then dried over anhydrous MgSO4, filtered and concentrated in 
vacuo. The crude product was then purified by column chromatography on silica gel to afford 
the corresponding target compound. 
(Z)-2-((3R,4S,5S,8S,9S,10S,11R,13R,14S,16S)-16-acetoxy-3-(benzoyloxy)-11-hydroxy-
4,8,10,14-tetramethylhexadecahydro-17H-cyclopenta[a]phenanthren-17-ylidene)-6-
methylhept-5-enoic acid [3.10] 
 
White solid (19 mg, 10% yield); m.p. 172 – 174 °C; Rf  0.31 (EtOAc:Hex, 1:1); 
1
H NMR 
(400 MHz, DMSO-d6) δH 8.00 – 7.92 (m, 2H, H
3’/7’
), 7.68–7.62 (m, 1H, H
5’
), 7.57 – 7.50 (m, 
2H, H
4’/6’
), 5.73 (d, J = 8.5 Hz, 1H, H
16
), 5.11 – 5.02 (m, 2H, H
3,24
), 4.20 – 4.08 (m, 1H, H
11
), 
2.97 – 2.88 (m, 1H, H
13
), 2.39 – 2.24 (m, 4H, H
1a,5,22
), 2.23 – 2.05 (m, 2H, H
12a,23a
), 2.05 – 
1.91 (m, 2H, H
15a,23a
), 1.88 (s, 3H, H
31
), 1.87 – 1.81 (m, 1H, H
2a
), 1.81 – 1.67 (m, 4H, 
H
2b,4,7a,12b
), 1.62 (s, 3H, H
27
), 1.60 – 1.56 (m, 1H, H
6a
), 1.55 (s, 3H, H
26
), 1.54 – 1.43 (m, 2H, 
H
1b,9
), 1.38 (s, 3H, H
30
), 1.16 (d, J = 14.1 Hz, 1H, H
15b
), 1.13 – 1.04 (m, 2H, H
6b,7b
), 0.98 (s, 
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3H, H
19
), 0.86 (s, 3H, H
18
), 0.81 (d, J = 6.6 Hz, 3H, H
28
); 
13
C NMR (100 MHz, DMSO-d6) δC 
169.9 (2C), 165.1, 143.7, 133.1, 130.9, 130.5, 129.1, 128.8 (2C), 128.8 (2C), 124.0, 75.0, 
73.7, 65.9, 48.5, 48.3, 42.9, 39.0, 38.7, 37.3, 36.3, 36.0, 34.7, 31.9, 30.1, 28.9, 28.3, 26.9, 
25.5, 23.7, 22.6, 20.6, 20.5, 17.7 (2C), 15.7; purity (LC-MS) 99%, tR = 5.31 min, MS m/z 
619.4 [M-H]
-
. 
(Z)-2-((3R,4S,5S,8S,9S,10S,11R,13R,14S,16S)-16-acetoxy-3-((4-fluorobenzoyl)oxy)-11-
hydroxy-4,8,10,14-tetramethylhexadecahydro-17H-cyclopenta[a]phenanthren-17-
ylidene)-6-methylhept-5-enoic acid [3.11] 
 
White solid (13 mg, 6% yield); m.p. 76 – 78 °C; Rf  0.38 (EtOAc:Hex, 3:7); 
1
H NMR (400 
MHz, CDCl3) δH 8.09 – 8.00 (m, 2H, H
3’/7’
), 7.18 – 7.07 (m, 2H, H
4’/6’
), 5.88 (d, J = 8.4 Hz, 
1H, H
16
), 5.21 – 5.16 (m, 1H, H
3
), 5.16 – 5.07 (m, 1H, H
24
), 4.43 – 4.32 (m, 1H, H
11
), 3.19 – 
3.08 (m, 1H, H
13
), 2.63 – 2.49 (m, 1H, H
22a
), 2.37 – 2.23 (m, 4H, H
1a,5,12a,22b
), 2.23 – 2.11 (m, 
3H, H
15a,23
), 2.02 (s, 3H, H
31
), 1.99 – 1.88 (m, 2H, H
2a,12b
), 1.88 – 1.74 (m, 3H, H
2b,4,7a
), 1.66 
(s, 3H, H
27
), 1.66 – 1.60 (m, 3H, H
1b,6a,9
), 1.59 (s, 3H, H
26
), 1.45 (s, 3H, H
30
), 1.36 (d, J = 
14.4 Hz, 1H, H
15b
), 1.24 – 1.08 (m, 2H, H
6b,7b
), 1.03 (s, 3H, H
19
), 0.97 (s, 3H, H
18
), 0.89 (d, J 
= 6.7 Hz, 3H, H
28
); 
13
C NMR (100 MHz, CDCl3) δC 170.9 (2C), 167.8, 165.1, 153.2, 133.1, 
131.9 (2C), 129.0, 125.3, 122.7, 115.5 (2C), 75.1, 74.1, 68.1, 49.1, 48.9, 44.7, 39.6, 39.1, 
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38.2, 37.0, 35.8, 35.1, 32.8, 31.2, 28.9, 28.6, 27.4, 25.7, 24.5, 22.7, 21.0, 20.6, 18.2, 17.8, 
15.8; purity (LC-MS) 98%, tR = 4.68 min, MS m/z 637.3 [M-H]
-
. 
(Z)-2-((3R,4S,5S,8S,9S,10S,11R,13R,14S,16S)-16-acetoxy-3-((4-chlorobenzoyl)oxy)-11-
hydroxy-4,8,10,14-tetramethylhexadecahydro-17H-cyclopenta[a]phenanthren-17-
ylidene)-6-methylhept-5-enoic acid [3.12] 
 
White solid (27 mg, 13% yield); m.p. 118 – 120 °C; Rf  0.24 (EtOAc:Hex, 1:1); 
1
H NMR (400 
MHz, CDCl3) δH 7.97 (d, J = 8.6 Hz, 2H, H
3’/7’
), 7.42 (d, J = 8.6 Hz, 2H, H
4’/6’
), 5.93 (d, J = 
7.1 Hz, 1H, H
16
), 5.22 – 5.14 (m, 1H, H
3
), 5.12 – 5.04 (m, 1H, H
24
), 4.38 – 4.30 (m, 1H, H
11
), 
3.11 – 2.97 (m, 1H, H
13
), 2.50 – 2.38 (m, 1H, H
22a
), 2.35 – 2.24 (m, 4H, H
1a,5,12a,22b
), 2.23 – 
2.09 (m, 3H, H
15a,23
), 1.96 (s, 3H, H
31
), 1.93 – 1.86 (m, 2H, H
2a,12b
), 1.86 – 1.74 (m, 3H, 
H
2b,4,7a
), 1.70 – 1.66 (m, 1H, H
6a
), 1.65 (s, 3H, H
27
), 1.65 – 1.58 (m, 2H, H
1b,9
), 1.58 (s, 3H, 
H
26
), 1.43 (s, 3H, H
30
), 1.33 (d, J = 14.2 Hz, 1H, H
15b
), 1.29 – 1.06 (m, 2H, H
6b,7b
), 1.02 (s, 
3H, H
19
), 0.94 (s, 3H, H
18
), 0.88 (d, J = 6.7 Hz, 3H, H
28
); 
13
C NMR (100 MHz, CDCl3) δC 
174.1, 170.7, 165.3, 150.8, 139.2, 132.6, 130.8 (2C), 129.4, 128.8 (2C), 123.0, 114.3, 75.4, 
74.4, 68.2, 49.1, 48.9, 44.3, 39.6, 39.0, 38.2, 37.0, 35.9, 35.1, 32.8, 31.2, 29.7, 28.8, 28.4, 
25.7, 24.5, 23.4, 22.6, 20.6, 18.1, 17.8, 15.8; purity (LC-MS) 99%, tR = 4.71 min, MS m/z 
653.3/655.3 [M-H]
-
. 
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(Z)-2-((3R,4S,5S,8S,9S,10S,11R,13R,14S,16S)-16-acetoxy-3-((4-bromobenzoyl)oxy)-11-
hydroxy-4,8,10,14-tetramethylhexadecahydro-17H-cyclopenta[a]phenanthren-17-
ylidene)-6-methylhept-5-enoic acid [3.13] 
 
White solid (54 mg, 24% yield); m.p. 179 – 181 °C; Rf  0.31 (MeOH:DCM, 0.4:9.6); 
1
H 
NMR (400 MHz, CD3OD) δH 7.94 (d, J = 8.7 Hz, 2H, H
3’/7’
), 7.65 (d, J = 8.7 Hz, 2H, H
4’/6’
), 
5.84 (d, J = 8.3 Hz, 1H, H
16
), 5.19 – 5.11 (m, 2H, H
3,24
), 4.33 – 4.27 (m, 1H, H
11
), 3.09 – 3.00 
(m, 1H, H
13
), 2.59 – 2.47 (m, 1H, H
22a
), 2.46 – 2.26 (m, 4H, H
1a,5,12a,22b
), 2.19 – 2.09 (m, 3H, 
H
15a,23
), 2.01 (s, 3H, H
31
), 1.98 – 1.75 (m, 5H, H
2,4,7a,12b
), 1.75 – 1.67 (m, 1H, H
6a
), 1.66 (s, 
3H, H
27
), 1.64 – 1.62 (m, 1H, H
9
), 1.61 (s, 3H, H
26
), 1.61 – 1.54 (m, 1H, H
1b
), 1.46 (s, 3H, 
H
30
), 1.24 (d, J = 14.1 Hz, 1H, H
15b
), 1.22 – 1.10 (m, 2H, H
6b,7b
), 1.05 (s, 3H, H
19
), 0.97 (s, 
3H, H
18
), 0.87 (d, J = 6.7 Hz, 3H, H
28
); 
13
C NMR (100 MHz, CD3OD) δC 179.5, 173.5, 166.8, 
139.3, 138.9, 133.0 (2C), 132.3, 132.1 (2C), 131.2, 128.9, 125.4, 77.3, 76.0, 68.5, 50.6, 50.0, 
43.8, 40.7, 40.3, 38.9, 37.9, 37.6, 36.9, 33.3, 31.8, 30.9, 29.2, 28.4, 25.9, 24.3, 23.5, 22.1, 
21.2, 18.2, 18.0, 16.3; purity (LC-MS) 99%, tR = 5.04 min, MS m/z 697.3/699.3 [M-H]
-
. 
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(Z)-2-((3R,4S,5S,8S,9S,10S,11R,13R,14S,16S)-16-acetoxy-3-((4-cyanobenzoyl)oxy)-11-
hydroxy-4,8,10,14-tetramethylhexadecahydro-17H-cyclopenta[a]phenanthren-17-
ylidene)-6-methylhept-5-enoic acid [3.14] 
 
White solid (28 mg, 13% yield); m.p. 161 – 163 °C; Rf  0.32 (MeOH:DCM, 0.4:0.96); 
1
H 
NMR (400 MHz, CD3OD) δH 8.10 (d, J = 8.6 Hz, 2H, H
3’/7’
), 7.79 (d, J = 8.6 Hz, 2H, H
4’/6’
), 
5.82 (d, J = 8.1 Hz, 1H, H
16
), 5.22 – 5.18 (m, 1H, H
3
), 5.17 – 5.11 (m, 1H, H
24
), 4.33 – 4.26 
(m, 1H, H
11
), 3.10 – 3.01 (m, 1H, H
13
), 2.60 – 2.46 (m, 1H, H
22a
), 2.46 – 2.26 (m, 4H, 
H
1a,5,12a,22b
), 2.20 – 2.08 (m, 3H, H
15a,23
), 2.01 (s, 3H, H
31
), 1.97 – 1.77 (m, 4H, H
2,7a,12b
), 1.76 
– 1.67 (m, 1H, H
4
), 1.66 (s, 3H, H
27
), 1.65 – 1.62 (m, 3H, H
1b,6a,9
), 1.61 (s, 3H, H
26
), 1.47 (s, 
3H, H
30
), 1.24 (d, J = 14.2 Hz, 1H, H
15b
), 1.22 – 1.11 (m, 2H, H
6b,7b
), 1.07 (s, 3H, H
19
), 0.97 
(s, 3H, H
18
), 0.88 (d, J = 6.7 Hz, 3H, H
28
); 
13
C NMR (100 MHz, CD3OD) δC 173.3 (2C), 
166.0, 139.8, 136.1, 133.6 (2C), 132.4, 131.1 (2C), 125.3, 119.0, 117.4, l78.0, 76.0, 68.5, 
50.6, 50.0, 43.9, 40.8, 40.3, 38.9, 37.9, 37.6, 36.9, 33.2, 31.7, 30.9, 30.7, 29.1, 28.3, 25.9, 
24.3, 23.5, 22.2, 21.0, 18.1, 17.9, 16.3; purity (LC-MS) 99%, tR = 4.56 min, MS m/z 644.3 
[M-H]
-
.  
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(Z)-2-((3R,4S,5S,8S,9S,10S,11R,13R,14S,16S)-16-acetoxy-11-hydroxy-4,8,10,14-
tetramethyl-3-((4-nitrobenzoyl)oxy)hexadecahydro-17H-cyclopenta[a]phenanthren-17-
ylidene)-6-methylhept-5-enoic acid [3.15] 
 
Off-white solid (32 mg, 14% yield); m.p. 135 – 137 °C; Rf  0.44 (MeOH:DCM, 0.5:9.5); 
1
H 
NMR (400 MHz, CD3OD) δH 8.33 (d, J = 9.0 Hz, 2H, H
3’/7’
), 8.25 (d, J = 9.0 Hz, 2H, H
4’/6’
), 
5.83 (d, J = 8.4 Hz, 1H, H
16
), 5.22 – 5.18 (m, 1H, H
3
), 5.16 – 5.09 (m, 1H, H
24
), 4.36 – 4.29 
(m, 1H, H
11
), 3.13 – 3.05 (m, 1H, H
13
), 2.59 – 2.49 (m, 1H, H
22a
), 2.48 – 2.28 (m, 4H, 
H
1a,5,12a,22b
), 2.23 – 2.01 (m, 3H, H
15a,23
), 1.97 (s, 3H, H
31
), 1.96 – 1.78 (m, 5H, H
2,4,7a,12b
), 
1.76 – 1.67 (m, 1H, H
6a
), 1.66 (s, 3H, H
27
), 1.65 – 1.61 (m, 2H, H
1b,9
), 1.60 (s, 3H, H
26
), 1.48 
(s, 3H, H
30
), 1.26 (d, J = 14.1 Hz, 1H, H
15b
), 1.24 – 1.13 (m, 2H, H
6b,7b
), 1.07 (s, 3H, H
19
), 
0.95 (s, 3H, H
18
), 0.89 (d, J = 6.7 Hz, 3H, H
28
); 
13
C NMR (100 MHz, CD3OD) δC 174.1, 
172.5, 165.6, 152.0, 148.6, 137.5, 133.3, 132.3, 131.6 (2C), 124.7 (2C), 124.4, 78.0, 75.7, 
68.3, 50.5, 50.0, 44.9, 40.7, 40.1, 38.8, 37.8, 37.5, 36.9, 33.1, 31.7, 29.9, 29.3, 28.3, 25.9, 
24.4, 23.6, 22.1, 20.7, 18.2, 17.9, 16.3; purity (LC-MS) 99%, tR = 4.76 min, MS m/z 664.3 
[M-H]
-
.  
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(Z)-2-((3R,4S,5S,8S,9S,10S,11R,13R,14S,16S)-16-acetoxy-11-hydroxy-4,8,10,14-
tetramethyl-3-((4-(trifluoromethyl)benzoyl)oxy)hexadecahydro-17H-
cyclopenta[a]phenanthren-17-ylidene)-6-methylhept-5-enoic acid [3.16] 
 
Off-white solid (71 mg, 35% yield); m.p. 171 – 173 °C; Rf  0.42 (EtOAc:Hex, 1:1); 
1
H NMR 
(400 MHz, CD3OD) δH 8.22 (d, J = 8.1 Hz, 2H, H
3’/7’
), 7.81 (d, J = 8.2 Hz, 2H, H
4’/6’
), 5.83 
(d, J = 8.3 Hz, 1H, H
16
), 5.21 – 5.18 (m, 1H, H
3
), 5.17 – 5.12 (m, 1H, H
24
), 4.33 – 4.28 (m, 
1H, H
11
), 3.09 – 3.02 (m, 1H, H
13
), 2.59 – 2.48 (m, 1H, H
22a
), 2.48 – 2.27 (m, 4H, 
H
1a,5,12a,22b
), 2.21 – 2.08 (m, 3H, H
15a,23
), 2.01 (s, 3H, H
31
), 2.00 – 1.77 (m, 5H, H
2,4,7a,12b
), 
1.77 – 1.67 (m, 1H, H
6a
), 1.66 (s, 3H, H
27
), 1.66 – 1.61 (m, 2H, H
1a,9
), 1.61 (s, 3H, H
26
), 1.48 
(s, 3H, H
31
), 1.25 (d, J = 14.3 Hz, 1H, H
15b
), 1.22 – 1.11 (m, 2H, H
6b,7b
), 1.07 (s, 3H, H
19
), 
0.97 (s, 3H, H
18
), 0.89 (d, J = 6.7 Hz, 3H, H
28
); 
13
C NMR (100 MHz, CD3OD) δC 173.4 (2C), 
166.3, 155.6, 140.0, 138.4, 135.7, 132.4, 131.1 (2C), 126.7 (2C), 126.6, 125.3, 77.7, 76.0, 
68.5, 50.6, 50.0, 43.9, 40.8, 40.3, 38.9, 37.9, 37.6, 36.9, 33.2, 31.7, 30.8, 29.2, 28.4, 25.9, 
24.3, 23.5, 22.2, 21.1, 18.1, 17.9, 16.3; purity (LC-MS) 99%, tR = 4.96 min, MS m/z 687.3 
[M-H]
-
.  
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(Z)-2-((3R,4S,5S,8S,9S,10S,11R,13R,14S,16S)-16-acetoxy-11-hydroxy-4,8,10,14-
tetramethyl-3-((4-(methylsulfonyl)benzoyl)oxy)hexadecahydro-17H-
cyclopenta[a]phenanthren-17-ylidene)-6-methylhept-5-enoic acid [3.17] 
 
White solid (81 mg, 39% yield); m.p. 177 – 179 °C; Rf  0.35 (EtOAc:Hex, 7:3); 
1
H NMR 
(400 MHz, CD3OD) δH 8.27 (d, J = 8.7 Hz, 2H, H
3’/7’
), 8.09 (d, J = 8.7 Hz, 2H, H
4’/6’
), 5.84 
(d, J = 8.2 Hz, 1H, H
16
), 5.22 – 5.18 (m, 1H, H
3
), 5.17 – 5.11 (m, 1H, H
24
), 4.33 – 4.27 (m, 
1H, H
11
), 3.17 (s, 3H, H
8’
), 3.10 – 3.01 (m, 1H, H
13
), 2.59 – 2.48 (m, 1H, H
22a
), 2.48 – 2.27 
(m, 4H, H
1a,5,12a,22b
), 2.20 – 2.08 (m, 3H, H
15a,23
), 2.01 (s, 3H, H
31
), 1.98 – 1.77 (m, 5H, 
H
2,4,7a,12b
), 1.77 – 1.68 (m, 1H, H
6a
), 1.66 (s, 3H, H
27
), 1.66 – 1.62 (m, 2H, H
1b,9
), 1.61 (s, 3H, 
H
26
), 1.48 (s, 3H, H
30
), 1.25 (d, J = 14.2 Hz, 1H, H
15b
), 1.23 – 1.11 (m, 2H, H
6b,7b
), 1.07 (s, 
3H, H
19
), 0.97 (s, 3H, H
18
), 0.89 (d, J = 6.7 Hz, 3H, H
28
); 
13
C NMR (100 MHz, CD3OD) δC 
173.3 (2C), 166.0, 145.9, 141.2, 137.6, 136.9, 132.6, 131.4 (2C), 128.8 (2C), 125.2, 78.0, 
76.0, 68.5, 50.9, 50.0, 44.1 (2C), 40.8, 40.3, 38.9, 37.9, 37.6, 36.9, 33.2, 31.7, 30.7, 29.2, 
28.3, 25.9, 24.3, 23.5, 22.1, 21.1, 18.2, 17.9, 16.3; purity (LC-MS) 99%, tR = 4.21 min, MS 
m/z 697.3 [M-H]
-
.  
 
Chapter 5: Experimental 
94 
 
(Z)-2-((3R,4S,5S,8S,9S,10S,11R,13R,14S,16S)-16-acetoxy-11-hydroxy-3-((4-
methoxybenzoyl)oxy)-4,8,10,14-tetramethylhexadecahydro-17H-
cyclopenta[a]phenanthren-17-ylidene)-6-methylhept-5-enoic acid [3.18] 
 
White solid (13 mg, 6% yield); m.p. 162 – 164 °C; Rf  0.47 (EtOAc:Hex, 7:3); 
1
H NMR (400 
MHz, CD3OD) δH 8.00 (d, J = 9.0 Hz, 2H, H
3’/7’
), 7.00 (d, J = 9.0 Hz, 2H, H
4’/6’
), 5.84 (d, J = 
8.5 Hz, 1H, H
16
), 5.20 – 5.08 (m, 2H, H
3,24
), 4.37 – 4.29 (m, 1H, H
11
), 3.86 (s, 3H, H
8’
), 3.15 
– 3.05 (m, 1H, H
13
), 2.61 – 2.49 (m, 1H, H
22a
), 2.48 – 2.26 (m, 4H, H
1a,5,12a,22b
), 2.25 – 2.04 
(m, 3H, H
15a,23
), 1.97 (s, 3H, H
31
), 1.95 – 1.78 (m, 5H, H
2,4,7a,12b
), 1.77 – 1.68 (m, 1H, H
6a
), 
1.67 (s, 3H, H
27
), 1.61 (s, 3H, H
26
), 1.61 – 1.56 (m, 2H, H
1b,9
), 1.49 (s, 3H, H
30
), 1.27 (d, J = 
13.8 Hz, 1H, H
15b
), 1.25 – 1.14 (m, 2H, H
6b,7b
), 1.07 (s, 3H, H
19
), 0.96 (s, 3H, H
18
), 0.88 (d, J 
= 6.7 Hz, 3H, H
28
); 
13
C NMR (100 MHz, CD3OD) δC 172.6 (2C), 167.7, 165.1, 148.4, 133.3 
(2C), 132.5 (2C) 124.4, 124.3, 114.9 (2C), 76.5, 75.8, 68.3, 56.0, 50.6, 50.0, 45.0, 40.8, 40.1, 
38.9, 37.9, 37.6, 37.0, 33.3, 31.8, 29.9, 29.3, 28.5, 25.9, 24.4, 23.4, 22.1, 20.7, 18.2, 17.9, 
16.3; purity (LC-MS) 99%, tR = 4.57 min, MS m/z 649.4 [M-H]
-
. 
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(Z)-2-((3R,4S,5S,8S,9S,10S,11R,13R,14S,16S)-16-acetoxy-11-hydroxy-4,8,10,14-
tetramethyl-3-((4-methylbenzoyl)oxy)hexadecahydro-17H-cyclopenta[a]phenanthren-
17-ylidene)-6-methylhept-5-enoic acid [3.19] 
 
Off-white solid (24 mg, 12% yield); m.p. 166 – 168 °C; Rf  0.26 (MeOH:DCM, 0.3:9.7); 
1
H 
NMR (400 MHz, CD3OD) δH 7.93 (d, J = 8.2 Hz, 2H, H
3’/7’
), 7.28 (d, J = 8.0 Hz, 2H, H
4’/6’
), 
5.82 (d, J = 8.2 Hz, 1H, H
16
), 5.19 – 5.10 (m, 2H, H
3,24
), 4.33 – 4.25 (m, 1H, H
11
), 3.07 – 2.98 
(m, 1H, H
13
), 2.58 – 2.47 (m, 1H, H
22a
), 2.40 (s, 3H, H
8’
), 2.40 – 2.25 (m, 4H, H
1a,5,12a,22b
), 
2.18 – 2.09 (m, 3H, H
15a,23
), 2.02 (s, 3H, H
31
), 1.99 – 1.77 (m, 5H, H
2,4,7a,12b
), 1.75 – 1.65 (m, 
1H, H
6a
), 1.65 (s, 3H, H
27
), 1.63 – 1.61 (m, 2H, H
1b,9
), 1.61 (s, 3H, H
26
), 1.47 (s, 3H, H
30
), 
1.24 (d, J = 14.1 Hz, 1H, H
15b
), 1.22 – 1.09 (m, 2H, H
6b,7b
), 1.05 (s, 3H, H
19
), 0.97 (s, 3H, 
H
18
), 0.87 (d, J = 6.7 Hz, 3H, H
28
); 
13
C NMR (100 MHz, CD3OD) δC 173.5 (2C), 167.9, 
145.0, 139.5, 138.1, 132.2, 130.5 (2C), 130.2 (2C), 129.2, 125.4, 76.6, 76.0, 68.5, 50.5, 50.0, 
43.6, 40.6, 40.3, 39.0, 37.9, 37.5, 36.8, 33.5, 31.8, 30.9, 29.1, 28.4, 25.9, 24.4, 23.3, 22.0, 
21.6, 21.2, 18.2, 18.0, 16.3; purity (LC-MS) 98%, tR = 4.60 min, MS m/z 633.4 [M-H]
-
. 
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(Z)-2-((3R,4S,5S,8S,9S,10S,11R,13R,14S,16S)-16-acetoxy-11-hydroxy-3-
(isonicotinoyloxy)-4,8,10,14-tetramethylhexadecahydro-17H-cyclopenta[a]phenanthren-
17-ylidene)-6-methylhept-5-enoic acid [3.20] 
 
White solid (20.1 mg, 11% yield); m.p. 184 – 186 °C; Rf  0.29 (MeOH:DCM, 0.5:9.5); 
1
H 
NMR (400 MHz, DMSO-d6) δH 8.83 (d, J = 4.9 Hz, 2H, H
4’
), 7.81 (d, J = 5.7 Hz, 2H, H
3’
), 
5.70 (d, J = 8.4 Hz, 1H, H
16
), 5.20 – 5.01 (m, 2H, H
3,24
), 4.30 – 4.08 (m, 1H, H
11
), 3.06 – 2.89 
(m, 1H, H
13
), 2.45 – 2.21 (m, 4H, H
1a,5,12a,23
), 2.21 – 1.92 (m, 3H, H
15a,23
), 1.89 (s, 3H, H
31
), 
1.83 – 1.65 (m, 5H, H
2,4,7a,12b
), 1.63 (s, 3H, H
27
), 1.62 – 1.57 (m, 1H, H
6a
), 1.55 (s, 3H, H
26
), 
1.54 – 1.41 (m, 2H, H
1b,9
), 1.38 (s, 3H, H
30
), 1.16 (d, J = 14.0 Hz, 1H, H
15b
), 1.13 – 1.03 (m, 
2H, H
6b,7b
), 0.98 (s, 3H, H
19
), 0.85 (s, 3H, H
18
), 0.81 (d, J = 6.6 Hz, 3H, H
28
); 
13
C NMR (100 
MHz, DMSO-d6) δC 171.1, 169.7, 164.0, 150.8 (2C), 147.0, 137.5, 131.5, 130.4, 123.3, 122.3 
(2C), 76.2, 73.5, 65.8, 48.5, 48.3, 43.2, 39.0, 38.6, 37.2, 36.2, 35.9, 34.7, 31.7, 30.0, 28.5, 
28.1, 26.7, 25.5, 23.7, 22.7, 20.6, 20.5, 17.6 (2C), 15.7; purity (LC-MS) 98%, tR = 4.37 min, 
MS m/z 620.4 [M-H]-.  
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(Z)-2-((3R,4S,5S,8S,9S,10S,11R,13R,14S,16S)-16-acetoxy-11-hydroxy-4,8,10,14-
tetramethyl-3-((pyrazine-2-carbonyl)oxy)hexadecahydro-17H-
cyclopenta[a]phenanthren-17-ylidene)-6-methylhept-5-enoic acid [3.21] 
 
White solid (20 mg, 9% yield); m.p. 116 – 118 °C; Rf  0.29 (MeOH:DCM, 0.5:9.5); 
1
H NMR 
(400 MHz, CD3OD) δH 9.30 (s, 1H, H
3’
), 8.86 – 8.78 (m, 2H, H
4’,5’
), 5.85 (d, J = 8.4 Hz, 1H, 
H
16
), 5.34 – 5.26 (m, 1H, H
3
), 5.19 – 5.11 (m, 1H, H
24
), 4.38 – 4.30 (m, 1H, H
11
), 3.15 – 3.07 
(m, 1H, H
13
), 2.63 – 2.51 (m, 1H, H
22a
), 2.49 – 2.30 (m, 4H, H
1a,5,12a,22b
), 2.25 – 2.01 (m, 3H, 
H
15a,23
), 1.99 (s, 3H, H
31
), 1.98 – 1.80 (m, 4H, H
2,4,7a,12b
), 1.79 – 1.70 (m, 1H, H
6a
), 1.68 (s, 
3H, H
27
), 1.68 – 1.63 (m, 2H, H
1b,9
), 1.63 (s, 3H, H
26
), 1.50 (s, 3H, H
31
), 1.29 (d, J = 14.4 Hz, 
1H, H
15b
), 1.27 – 1.15 (m, 2H, H
6b,7b
), 1.10 (s, 3H, H
19
), 0.98 (s, 3H, H
18
), 0.94 (d, J = 6.8 Hz, 
3H, H
28
); 
13
C NMR (100 MHz, CD3OD) δC 174.3, 172.6, 164.8, 149.1, 148.5, 146.8, 146.1, 
145.1, 133.3, 132.4, 124.4, 78.8, 75.7, 68.3, 50.6, 50.0, 44.9, 40.7, 40.1, 38.8, 37.8, 37.5, 
36.9, 33.1, 31.7, 29.9, 29.3, 28.3, 25.9, 24.3, 23.5, 22.1, 20.7, 18.2, 17.9, 16.2; purity (LC-
MS) 97%, tR = 4.28 min, MS m/z 621.4 [M-H]
-
.  
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(Z)-2-((3R,4S,5S,8S,9S,10S,11R,13R,14S,16S)-16-acetoxy-4,8,10,14-tetramethyl-3,11-
bis((pyrazine-2-carbonyl)oxy)hexadecahydro-17H-cyclopenta[a]phenanthren-17-
ylidene)-6-methylhept-5-enoic acid [3.22] 
 
White solid (32 mg, 12% yield); m.p. 134 – 136 °C; Rf  0.29 (MeOH:DCM, 0.5:9.5); 
1
H 
NMR (400 MHz, CD3OD) δH 9.18 (d, J = 1.2 Hz, 1H, H
3’
), 9.06 (d, J = 1.4 Hz, 1H, H
8’
), 8.80 
(d, J = 2.4 Hz, 1H, H
5’
), 8.73 (dd, J = 2.5, 1.4 Hz, 1H, H
4’
), 8.71 – 8.68 (m, 2H, H
9’,10’
), 5.84 
(d, J = 8.5 Hz, 1H, H
16
), 5.76 – 5.66 (m, 1H, H
11
), 5.28 – 5.18 (m, 1H, H
3
), 5.04 – 4.95 (m, 
1H, H
24
), 3.04 – 2.90 (m, 1H, H
13
), 2.66 – 2.57 (m, 1H, H
22a
), 2.54 – 2.42 (m, 2H, H
5,12a
), 
2.41 – 2.31 (m, 1H, H
12b
), 2.31 – 2.21 (m, 1H, H
15a
), 2.09 – 1.99 (m, 2H, H
9,22b
), 1.98 (s, 3H, 
H
31
), 1.97 – 1.85 (m, 6H, H
1a,2a,4,7a,23
), 1.85 – 1.74 (m, 2H, H
2b,6a
), 1.69 (s, 3H, H
27
), 1.44 (s, 
3H, H
26
), 1.43 (s, 3H, H
30
), 1.42 – 1.39 (m, 2H, H
1b,7b
), 1.36 (d, J = 14.2 Hz, 1H, H
15b
), 1.34 – 
1.21 (m, 1H, H
6b
), 1.16 (s, 3H, H
19
), 1.04 (s, 3H, H
18
), 0.92 (d, J = 6.7 Hz, 3H, H
28
);
 13
C 
NMR (100 MHz, CD3OD) δC 173.7, 172.4, 164.8, 164.5, 149.0, 148.8, 147.2, 146.5, 146.3 
(2C), 146.1, 144.8, 144.7, 133.4, 132.7, 123.7, 78.0, 75.4, 74.4, 49.9, 49.8, 45.1, 40.8, 39.9, 
38.6, 37.9, 36.6, 33.1, 32.9, 31.0, 29.6, 28.6, 28.0, 25.8, 24.5, 23.3, 21.7, 20.7, 18.2, 17.7, 
16.1; purity (LC-MS) 90%, tR = 4.17 min, MS m/z 727.3 [M-H]
-
. 
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5.2.5 Procedure for the synthesis and characterization C-3 amine series 
5.2.5.1 Intermediate 3.23 
(3R,4S,5S,8S,9S,10S,11R,13R,14S,16S,Z)-17-(1-hydrazineyl-6-methyl-1-oxohept-5-en-2-
ylidene)-3,11-dihydroxy-4,8,10,14-tetramethylhexadecahydro-1H-
cyclopenta[a]phenanthren-16-yl acetate [3.23] 
 
To a solution of fusidic acid (4.26 g, 8.24 mmol) in acetonitrile (10 mL), HOBt (1.47 g, 9.89 
mmol) and EDCI (1.85 g, 9.89 mmol) were added subsequently while stirring at 25 °C for 3 
hrs. Hydrazine hydrate (1.60 mL, 32.96 mmol) was then added with continuous stirring at 25 
°C. After completion of reaction (TLC), the reaction mixture was concentrated under reduced 
pressure and the residue taken up in DCM (30 mL) and washed with water (3×30 mL). The 
organic layer was dried over anhydrous MgSO4, filtered and concentrated in vacuo. The 
crude product was then purified by column chromatography on silica gel using 70% 
EtOAc/Hexane as eluent, which after washing with pentane afforded white solid (4.05 g, 86% 
yield); m.p. 113 – 115 °C; Rf 0.37 (MeOH:DCM:NH4OH, 0.9:9:0.1); 
1
H NMR (400 MHz, 
CD3OD) δH 5.78 (d, J = 8.4 Hz, 1H, H
16
), 5.18 – 5.07 (m, 1H, H
24
), 4.35 – 4.28 (m, 1H, H
11
), 
3.71 – 3.62 (m, 1H, H
3
), 3.10 – 2.99 (m, 1H, H
13
), 2.59 – 2.48 (m, 1H, H
22a
), 2.32 – 2.21 (m, 
2H, H
12a,22b
), 2.21 –2.03 (m, 5H, H
1a,5,15a,23
), 1.99 (s, 3H, H
31
), 1.89 – 1.69 (m, 4H, H
2,7a,12b
), 
1.68 (s, 3H, H
27
), 1.61 (s, 3H, H
26
), 1.61 – 1.58 (m, 1H, H
9
), 1.58 – 1.44 (m, 3H, H
1b,4,6a
), 
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1.39 (s, 3H, H
30
), 1.20 (d, J = 14.2 Hz, 1H, H
15b
), 1.18 – 1.07 (m, 2H, H
6b,7b
), 1.00 (s, 3H, 
H
19
), 0.95 (s, 3H, H
18
), 0.90 (d, J = 6.8 Hz, 3H, H
28
);
 13
C NMR (100 MHz, CD3OD) δC 173.1, 
172.4, 144.9, 133.9, 133.2, 124.4, 75.0, 72.4, 68.5, 50.7, 49.9, 44.6, 40.7, 40.2, 38.2, 37.8, 
37.3, 36.8, 32.9, 31.0 (2C), 30.4, 28.7, 25.9, 23.8 (2C), 22.4, 21.1, 17.9 (2C), 16.5; purity 
(LC-MS) 99%, MS m/z 529.3 [M-H]
-
. 
5.2.5.2 Intermediate 3.24 
(3R,4S,5S,8S,9S,10S,11R,13R,14S,16S,Z)-3,11-dihydroxy-4,8,10,14-tetramethyl-17-(6-
methyl-1-(2-(methylsulfonyl)hydrazinyl)-1-oxohept-5-en-2-ylidene)hexadecahydro-1H-
cyclopenta[a]phenanthren-16-yl acetate [3.24] 
 
Methanesulfonyl chloride (0.63 mL, 8.12 mmol) was added to a solution of compound 3.23 
(4.31 g, 8.12 mmol) in pyridine (20 mL) while stirring at 25 °C. After completion of reaction 
(TLC), the reaction mixture was diluted with ethyl acetate (30 mL) and washed with water 
(3×30 mL) and 0.5 M aq. HCl (3×30 mL). The organic layer was dried over anhydrous 
MgSO4, filtered and concentrated in vacuo. The crude product was then purified by column 
chromatography on silica gel using 70% EtOAc/Hexane as eluent, which after washing with 
pentane afforded white solid (4.46 g, 90% yield); m.p. 125 – 127 °C; Rf  0.42 (EtOAc:DCM, 
8:2); 
1
H NMR (400 MHz, CDCl3) δH 8.16 (s, 1H, H
CONH
), 7.10 (br s, 1H, H
SO
2
NH
), 5.73 (d, J 
= 8.2 Hz, 1H, H
16
), 5.15 – 5.05 (m, 1H, H
24
), 4.39 – 4.30 (m, 1H, H
11
), 3.79 – 3.70 (m, 1H, 
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H
3
), 3.06 – 3.00 (m, 1H, H
13
), 3.00 (s, 3H, H
32
), 2.49 – 2.40 (m, 1H, H
22a
), 2.38 – 2.22 (m, 
2H, H
12a,22b
), 2.21 – 2.07 (m, 5H, H
1a,5,15a,23
), 1.99 (s, 3H, H
31
), 1.93 – 1.69 (m, 4H, H
2,7a,12b
), 
1.67 (s, 3H, H
27
), 1.60 (s, 3H, H
26
), 1.58 – 1.53 (m, 3H, H
4,6a,9
), 1.52 – 1.46 (m, 1H, H
1b
), 
1.37 (s, 3H, H
30
), 1.27 (d, J = 14.2 Hz, 1H, H
15b
), 1.17 – 1.04 (m, 2H, H
6b,7b
), 0.97 (s, 3H, 
H
19
), 0.93 (s, 3H, H
18
), 0.91 (d, J = 6.9 Hz, 3H, H
28
); 
13
C NMR (100 MHz, CDCl3) δC 170.8, 
170.6, 145.9, 133.1, 131.7, 122.7, 73.8, 71.5, 68.3, 49.4, 48.8, 43.8, 39.6, 39.4, 39.3, 37.0, 
36.4, 36.0, 35.5, 32.1, 30.2, 29.8, 29.7, 28.3, 25.7, 23.9, 23.0, 21.2, 20.8, 17.9, 17.8, 15.9; 
purity (LC-MS) 83%, tR = 4.49 min, MS m/z 549.3 [M-OAc]
+
. 
5.2.5.3 Intermediate 3.25 
(4S,5S,8S,9S,10S,11R,13R,14S,16S,Z)-11-hydroxy-4,8,10,14-tetramethyl-17-(6-methyl-1-
(2-(methylsulfonyl)hydrazinyl)-1-oxohept-5-en-2-ylidene)-3-oxohexadecahydro-1H-
cyclopenta[a]phenanthren-16-yl acetate [3.25]  
 
Jones reagent (0.35 mL, 1.06 mmol, 2.98 mM) was added dropwise to a solution of 
compound 3.24 (2.48 g, 4.08 mmol) in acetone (8.00 mL) with stirring in an ice bath over 30 
mins after which the reaction was stirred for an additional 10 mins, before being diluted with 
water (30 mL) and extracted with EtOAc (3×30 mL). The organic layer was then dried over 
anhydrous NaSO4, filtered and concentrated under reduced pressure. The crude product was 
then purified by column chromatography on silica gel using 50% EtOAc/Hexane as eluent, 
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which after washing with pentane afforded a white solid (730 mg, 29% yield); m.p. 123 – 125 
°C; Rf  0.31 (EtOAc:DCM, 1:1); 
1
H NMR (400 MHz, CDCl3) δH 7.96 (d, J = 4.5 Hz, 1H, 
H
CONH
), 6.98 (d, J = 4.5 Hz, 1H, H
SO
2
NH
), 5.73 (d, J = 8.0 Hz, 1H, H
16
), 5.16 – 5.06 (m, 1H, 
H
24
), 4.43 – 4.35 (m, 1H, H
11
), 3.07 – 3.00 (m, 1H, H
13
), 3.00 (s, 3H, H
32
), 2.53 – 2.41 (m, 
3H, H
2,22a
), 2.38 – 2.23 (m, 4H, H
1a,5,12a,22b
), 2.19 – 2.08 (m, 3H, H
15a,23
), 2.00 (s, 3H, H
31
), 
1.99 – 1.83 (m, 4H, H
1b,4,7a,12b
), 1.68 (s, 3H, H
27
), 1.66 – 1.61 (m, 2H, H
6a,9
), 1.60 (s, 3H, 
H
26
), 1.32 (d, J = 14.2 Hz, 1H, H
15b
), 1.29 (s, 3H, H
30
), 1.28 – 1.16 (m, 2H, H
6b,7b
), 1.15 (s, 
3H, H
19
), 1.00 (d, J = 6.6 Hz, 3H, H
28
), 0.96 (s, 3H, H
18
); 
13
C NMR (100 MHz, CDCl3) δC 
213.5, 170.6, 170.5, 146.1, 133.3, 132.1, 122.6, 73.8, 68.1, 48.9, 48.4, 45.7, 45.4, 43.8, 39.5, 
39.3, 39.2, 38.0, 37.0, 36.0, 35.4, 33.6, 29.7, 28.2, 25.7, 24.7, 22.6, 21.8, 21.2, 18.2, 17.8, 
12.3; purity (LC-MS) 99%, tR = 4.25 min, MS m/z 605.3 [M-H]
-
. 
5.2.5.4 Target compound 3.26 
(4S,5S,8S,9S,10S,11R,13R,14S,16S,Z)-11-hydroxy-4,8,10,14-tetramethyl-17-(6-methyl-1-
(2-(methylsulfonyl)hydrazineyl)-1-oxohept-5-en-2-ylidene)-3-
(methylamino)hexadecahydro-1H-cyclopenta[a]phenanthren-16-yl acetate [3.26] 
 
To a solution of 3.25 (90 mg, 0.15 mmol) in DCE (4.00 mL), methylamine (0.02 mL, 0.44 
mmol), Na(OAc)3BH (319 mg, 1.48 mmol) and AcOH (0.02 mL, 0.30 mmol) were added and 
the mixture stirred under N2 atmosphere at 60 °C for 48 hrs. After completion of reaction 
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(TLC), the reaction mixture was quenched with 1 N aq. NaHCO3, extracted with EtOAc (30 
mL) and washed with water (3×30 mL). The organic layer was dried over anhydrous MgSO4, 
filtered and concentrated in vacuo. The crude product was then purified by prep-TLC using 
9% MeOH/DCM as eluent, which after washing with pentane afforded a white solid (10.8 
mg, 12% yield); m.p. 137 – 139 °C; Rf 0.20 (MeOH:DCM:NH4OH, 0.9:9.05:0.05); a 1:1 
mixture of diastereomers; 
1
H NMR (400 MHz, CDCl3) δH 7.11 (d, J = 8.7 Hz, 1H, H
CONH
), 
6.80 (d, J = 8.8 Hz, 1H, H
SO
2
NH
), 5.73 (d, J = 8.3 Hz, 1H, H
16
), 5.18 – 5.03 (m, 1H, H
24
), 4.50 
– 4.34 (m, 1H, H
11
), 2.98 (s, 3H, H
32
), 2.96 – 2.92 (m, 1H, H
13
), 2.51 – 2.43 (m, 1H, H
3
), 2.37 
(s, 3H, H
1’
), 2.35 – 2.24 (m, 1H, H
22a
), 2.23 – 2.03 (m, 8H, H
1,5,12a,15a,22b,23
), 2.01 (s, 3H, H
31
), 
1.98 – 1.83 (m, 2H, H
2
), 1.83 – 1.72 (m, 1H, H
12b
), 1.65 (s, 3H, H
27
), 1.64 – 1.58 (m, 3H, 
H
4,6a,9
), 1.58 (s, 3H, H
26
), 1.47 – 1.41 (m, 1H, H
7a
), 1.39 (s, 3H, H
30
), 1.19 (d, J = 14.4 Hz, 
7H, H
15b
), 1.15 – 1.00 (m, 2H, H
6b,7b
), 0.99 (s, 3H, H
19
), 0.92 (s, 3H, H
18
), 0.88 (d, J = 6.8 Hz, 
3H, H
28
); 
13
C NMR (100 MHz, CDCl3) δC 172.0, 170.4, 143.4, 132.6, 132.5, 123.1, 73.9, 
68.1, 61.5, 49.9, 48.6, 43.5, 40.3, 39.7, 39.1, 36.6, 36.4, 35.5, 35.3, 35.0, 30.1, 29.8, 29.7, 
28.3, 25.6, 24.9, 24.2, 22.8, 21.6, 21.3, 17.7, 17.1, 15.9; purity (LC-MS) 80%, tR = 3.44 min, 
MS m/z 620.3 [M-H]
-
. 
5.3 Biological assay procedure 
The minimum inhibitory concentration (MIC) was determined using the standard broth 
micro dilution method on a single 96-well microtiter plate.
118,119
 A 10 mL culture of 
Mycobacterium tuberculosis H37RvMa is grown for the Alamar Blue assay.
120
 The cultures 
are grown to an optical density (OD600) of 0.6 – 0.7. 
The media used are:  
(i) GAST/Fe (glycerol–alanine–salts) medium pH 6.6, supplemented with 0.05% 
Tween- 80 and 1% Glycerol.
121,122
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(ii) 7H9 supplemented with 10% Albumin Dextrose Catalase supplement (ADC), 
0.05% Tween-80 and 0.2% D-glucose.
123
  
Cultures grown in GAST/Fe are diluted to 1:100, and cultures grown in 7H9 ADC are diluted 
to 1:500, prior to inoculation of the MIC assay.  
The compounds to be tested are reconstituted to a concentration of 10 mM in DMSO. Two-
fold serial dilutions of the test compound are prepared across a 96-well micro titre plate, after 
which, 50 µL of the diluted respective M. tuberculosis culture was added to each well from 
rows 2-12 in a serial dilution. The plate layout is a modification of the method previously 
described.
124
 Assay controls used are a minimum growth control (Rifampicin at 2x MIC) and 
a maximum growth control (5% DMSO).  
The micro titre plates are sealed in a secondary container and incubated at 37 °C with 5% 
CO2 and humidification to prevent evaporation of the liquid. The lowest concentration of 
drug that inhibits growth of more than 99 % of the bacterial population is considered to be the 
MIC99. The MIC values were then recorded at 7- and 14-days post inoculation of the assay, 
by observing the presence or absence of a bacterial pellet. 10 µL of Alamar Blue (resazurin) 
is added at day 13 and the assay plate is re-incubated for another 24 hrs. A visual score is 
obtained by observation of a color change, from blue (no bacterial growth) to pink (growth), 
at day-14.  
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Appendices 
Appendix 1: Key COSY correlations of fusidic acid (3.1) in CDCl3 
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Appendix 2: Stacked 
1
H-NMR spectra of compounds 3.1 and 3.2 in DMSO-d6 
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Appendix 3: Stacked 
1
H-NMR spectra of compounds 3.1, 3.4, 3.6 and 3.8 in CDCl3 
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Appendix 4: Stacked 
1
H-NMR spectra of compounds 3.1 and 3.13 in CD3OD 
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Appendix 5: Stacked 
1
H-NMR spectra of compounds 3.1, 3.21 and 3.22 in CD3OD 
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Appendix 6: Stacked 
1
H-NMR spectra of compounds 3.1, 3.24, 3.25 and 3.26 in CDCl3 
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